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Chapter 1 
Introduction and 
Objectives of this Thesis 
This chapter is a modi­
fied version of: Genetic 
Variation in Genes of the 
Folate MetaboLism and 
Neural Tube Defect Risk 
Ivon JM van der Linden, 
Lydia A Afman, Sandra G 
Heil and Henk J Blom 
Proceedings of The Nutrition Society 200ό, 65: 204-215 
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J Introduction and Objectives of this Thesis 
1 The neural tube 
Neural tube closure 
1 Λ Closure of the neural tube is a fundamental event during embryogenesis, • I · giving rise to the central nervous system (CN5) and most of the peri­
pheral nervous system (PNS)1 Neural tube closure occurs during the third and 
fourth week of gestation at a time when most women are only just aware of the 
fact that they are pregnant Data on neurulation in human embryos is sparse2 ' and 
most of our knowledge on the cellular and molecular events that happen at the 
time of neural tube closure is obtained from animal studies5 6 
In mammalian embryos neurulation is divided into a primary and secondary phase 
Primary neurulation gives rise to the brain and most of the spinal cord, whereas 
secondary neurulation is restricted to the tail bud or caudal eminence, forming the 
lowest part of the spinal cord at the lower sacral and coccygeal region Secondary 
neurulation occurs by condensation and canalization of mesenchymal cells, a com­
pletely different process than primary neurulation6 
This thesis wi l l focus on the primary neurulation during which the brain and most 
of the spinal cord are formed by shapenmg, folding and midline fusion of the neural 
plate 
Neural plate formation and shapening 
1 Λ Λ Neurulation begins with the formation of the neural plate During neural • I · I plate formation, the midline dorsal ectoderm of the embryo thickens 
and cell shape changes into a pseudostratified columnar epithelium6 Subsequently, 
the elliptical neural plate is transformed into an elongated keyhole shaped struc­
ture with broad cranial and narrow caudal regions The driving mechanism of neural 
plate shapening is convergent extension, which is a medially cell movement with 
intercalation of cells m the midline, resulting in the narrowing and lengthening of 
the neural plate7 
Neural plate folding 
1 Λ f\ After the formation of the neural plate, the edges of the neural plate • 1·£. will elevate giving rise to the neural folds The neural folds subsequently 
bend and elevate, which results in the formation of the neural groove Neural fold 
elevation and bending differs in morphology along the body axis of the developing » 
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embryo [figure 1)7. At the most caudal part of the spine bending occurs solely at 
paired dorsolateral hinge points (DLHPs), while at intermediate levels the neural 
plate bends at both DLHPs and the median hinge point (MHP) and al the upper 
levels of the spine bending occurs solely at the MHP. Elevation and bending of the 
cranial neural folds differs from that in the spinal cord m that elevation starts with 
expansion of the cranial mesenchyme underlying the neural plate, which results 
m biconvex neural folds that subsequently flip around, become biconcave and ap­
pose in the dorsal midline. Both the actm cytoskeleton and neural crest migration 
are considered to play an important role m the elevation and bending of the cranial 
neural folds7. 
Fusion of the neural folds 
I I O The apical cells of the apposing neural folds contain cell protrusions 
' · ' · 0 that mterdigitate, resulting m the adhesion and fusion of the neural 
folds6 7. After neural fold fusion, the newly formed neural tube and the surface ecto­
derm are separated and the surface ectoderm wil l become the epidermis overlying 
the neural tube 
Since the observation that the closure of the neural tube initiates at different sites in 
several animal models, this multi-site closure model was also proposed for the hu­
man embryo' The number of closure initiation sites suggested for human embryos 
ranges from five to two and also the location is debated3 4 9. The most recent study 
in human embryos identified only two closure initiation sites (a and β]4. The α clo­
sure site is located in the rhombencephalic region of the embryo and extends both 
rostrally and caudally wit the caudal extension forming the posterior neuropore. The 
β closure site, located m the prosencephalic region of the embryo, proceeds rostro-
caudally from the rostral end of the neural plate and meets the cranial extension of 
the α closure site to close the anterior neuropore' 
1.2 Neural tube defects 
Classification 
1 Λ si Failure of the neural tube to close wil l result in neural tube defects • fc· I (NTDs] There are many forms of NTDs varying in location, level and se­
venty of the lesion (figure 2 ) ' , 0 " Failure of the cranial neural folds to fuse wil l result 
m anencephaly, which is characterized by the absence of the calvana and partial » 
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or total absence of the brain. Anencephaly is not compatible with life and children 
die in utero or shortly after birth111. Encephalocele is another, more rare, cranial 
defect that involves the herniation of the brain and meninges through a bony defect 
in the skull1 " . Closure defects in which both the brain and spinal cord remain open 
are referred to as craniorachischisis and are severe defects that are not compatible 
with life1. 
Spina bifida refers to closure defects in the caudal part of the spinal cord and can 
be classified into open and closed spina bifida10. Open spina bifida usually occurs at 
the lumbar or lumbosacral levels. Myelomeningocele accounts for the vast majority 
of open spina bifida cases and is characterized by the herniation of the spinal cord 
and nerves through a bony defect in the spine, resulting m the exposure of neural 
tissue to the environment10. As a result of extensive medical care open spina bifida 
is nowadays compatible with life, although infants with spina bifida that survive are 
likely to have severe disabilities and are at risk for psychosocial maladjustment. 
Closed spina bifida is a relatively mild defect and is even more heterogeneous than 
open spina bifida10. In closed spina bifida, lesions are covered with skin and hence 
the neural tissue is not exposed to the environment. Closed spina bifida is rarely 
included m studies, partly because it is not always detected at birth. The most com-
mon forms of NTDs are anencephaly and myelomeningocele. 
Prevalence 
With a worldwide prevalence of approximately 1 per 1000 births NTDs 1.2.2 are the second most common congenital malformations after congeni-
tal heart defects. The prevalence of NTD affected births vanes considerably by geo-
graphic area and ethnicity with prevalences as high as almost 14 per 1000 births 
during the year 2003 m north central China12, about 0.7 per 1000 births m the pe-
riod 1999-2003 m the United States13 and about 1.5 per 1000 births in the period 
1988-1998 m The Netherlands13 u . However, NTD prevalence is not a very reliable 
estimate of the incidence of NTDs, because NTD prevalence often only includes live-
and stillbirths and not pregnancy terminations, which have increased dramatically 
over the past years. 
Risk factors 
Not taking into account the small percentage of NTDs that are associ-1.2.3 ated with chromosomal or single gene disorders, NTDs are believed 
to have a multifactorial etiology with interplay of both genetic and environmental 
18 
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factors. The higher recurrence rate of NTDs within families, the preponderance of 
NTDs m monozygotic twins1516 and the association between NTDs and ethnicity are 
several observations that imply genetic factors to be involved m NTD etiology. Dif-
ferences in NTD prevalence in t ime", between seasons17, geographical areas117 and 
socioeconomic status18 indicate that environmental factors are also involved in NTD 
etiology. Specific risk factors for NTDs that have been identified include maternal 
diabetes mell i tus"20 , maternal obesity2123, maternal use of antiepileptic drug such 
as valproic acid24, hyperthermia2526 and paternal occupation2728. 
Animal models 
1.2.4 
Neurulation can and has been studied in many different animal mod-
els including mouse29, rat30, pig31, rabbit32 and chick3334 models. The 
mouse is by far the most frequently studied animal model m relation to neural tube 
closure. At this moment there are over 190 mouse mutants and strains that exhibit 
NTDs among which are 155 that involve known genes, 33 with unidentified genes 
and 8 multifactorial strains29. Mouse models with NTDs can be studied to identify 
molecular pathways crucial for proper neural tube closure7, but can also be used to 
study the effect of exogenous and teratogenic agents on neural tube closure35. An-
other widely used animal model to study neural tube closure is the chick embryo. 
The advantages of a chick embryo model above other animal species are the easy 
accessibility and possibility to manipulate the embryos both in ovo36 and in vitro3738. 
The advantage of the in vitro model above the in ovo model is the possibility to 
closely monitor the effects of manipulation on the closure of the neural tube. 
2 Folate 
Folic acid 
2.1 In 1976 Smithells et al. demonstrated decreased levels of several micronu-tnents, especially folate, m serum of women pregnant with a NTD affected 
child during the first trimester39. Subsequent small trials in women who had a NTD 
affected pregnancy demonstrated that penconceptional supplementation with 0.4 
to 5 mg of folic acid per day, decreased the recurrence risk of NTDs about fourfold 
(figure 3]4046. In 1991, the MRC Vitamin Study Research group conducted a large 
19 
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multiinstitutional double-blind placebo-controlled randomized trial in 1817 women 
who had a NTD affected pregnancy and demonstrated a 72% reduction m NTD recur­
rence risk for periconceptional folic acid supplementation (figure 3)". The protec­
tive effect of periconceptional folic acid supplementation on NTD occurrence risk has 
mainly been demonstrated in retrospective case-control studies (figure 4)48 51. However a 
large randomized controlled trial m Hungarian women showed that supplementation 
with multivitamins including 0.8 mg folic acid reduced the first occurrence of NTDs 
with 93% (figure A)52. 
Figure 3 
M e t a - a n a l y s i s f o r t h e r e d u c t i o n in N T D r e c u r r e n c e r i s k o b s e r v e d 
w i t h p e r i c o n c e p t i o n a l f o l i c a c i d s u p p l e m e n t a t i o n 
Smilhel ls 1980 
Laurence 1981 
Smithel ls198l 
Smithells 1983 • 
Seller 1984 • 
Smithed 1989 • 
Vergei 1990 • 
MRC study 1991 • 
Kirke 1992 • 
Combined — 
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- ^ 0R=0 21 lO 12 O36I 
ι — Odds ratio 
The results of these studies led to the general advice for women planning a preg­
nancy to take 0.Λ mg of folic acid per day at least one month before conception and 
during the first trimester of pregnancy53. Women who are at high risk because of a 
previous NTD affected pregnancy were advised to take Λ mg of folic acid daily in the 
periconceptional period5 3. Years after the endorsement of these recommendations, 
the expected decline m NTD prevalence failed to occur and in 1998 the United States 
mandated folic acid fortification of enriched cereal gram products. In contrast to the 
recommendations, folic acid fortification resulted in a decline of NTD rates with 20-
20 
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Figure 4 
M e t a - a n a l y s i s f o r t h e r e d u c t i o n in N T D o c c u r r e n c e r i s k o b s e r v e d w i t h 
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Folate uptake and transport 
2.2 The water-soluble B-vitamin folate is an essential vitamin for humans and is obtained from the diet. According to chemical nomenclature, the difference 
between folate and folic acid is just one proton. In general, the term folic acid is ap­
plied to the synthetic form of this B-vitamin, which is more stable53-5'1. Dietary folates 
predominantly exist as polyglutamates, which have to be hydrolyzed to monogluta-
mates in order to be transported. The enzyme folylpoly-y-glutamate carboxypepti-
dase (FGCP) that is anchored to the intestinal apical brush border and is encoded by 
the glutamate carboxypeptidase II (GCPII) gene is responsible for this hydrolyzation 
(figure 5|55. Monoglutamylated folates are subsequently absorbed in the duodenum 
and upper part of the jejunum by the high-affinity proton-coupled folate receptor 
PCFT/HCP156 (figure 5). 5-Methyltetrahydrofolate (5-methylTHF] is the main circu­
lating form of folate in the plasma and can be transported into the cell by means of 
carrier- or receptor-mediated transport (figure 5). Folate receptor α (FR-al is a glyco-
sylphosphatidylinositol linked glycoprotein with a high affinity for the monoglutamate 
5-methylTHF and is expressed in a limited number of epithelial cells, predominantly 
in the proximal tubules of the kidney, the choroid plexus and the placenta57 59. The 
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other folate receptors, β and γ, have a much lower affinity for 5-methylTHF than FR-
α Carrier-mediated transport occurs via the ubiquitously expressed reduced folate 
carrier (RFC) whose affinity for 5-methylTHF is also considerably lower than that of 
the FR-a 
Folate cycle 
2 r\ In the cell, 5-methylTHF can function as a methyl donor for homocyste-• O me remethylation with subsequent formation of THF THF can directly be 
converted into 5,10-methyleneTHF by the action of serine hydroxymethyltransferase 
[SHMT]60 SHMT is a vitamin B6 dependent enzyme that uses serine as a one-carbon 
donor In humans SHMT has both a cytosolic and mitochondrial isoform6 0 Indirect 
conversion of THF into 5,10-methyleneTHF, via 10-formylTHF and 5,10-methenyl-
THF, is catalyzed by the tnfunctional enzyme methylenetetrahydrofolate dehydro­
genase (MTHFD1) that has both formyltetrahydrofolate synthetase, methenyltetra-
hydrofolate cyclohydrolase and methylenetetrahydrofolate dehydrogenase activity61 
The 10-formylTHF formed out of THF can donate one-carbon groups for purine bio­
synthesis, whereas 5,10-methylenetetrahydrotolate can be used as a cofactor for the 
conversion of dUMP into dTMP This reaction is catalyzed by the thymidylate synthase 
(TYMS) enzyme and renders dihydrofolate (DHF) that can be reduced back to THF by 
the action of dihydrofolate reductase (DHFR) Besides a cofactor for dTMP synthesis, 
5,10-methyleneTHF can also be reduced to 5-methylTHF by the vitamin B2 depen­
dent enzyme methylenetetrahydrofolate reductase (MTHFR), which is hereby com­
peting for 5,10-methyleneTHF with TYMS The MTHFR enzyme is of great importance 
for the regulation of available 5-methylTHF for homocysteine remethylation (figure 
6) 
3 Homocysteine metabolism 
Remethylation 
3
s* Homocysteine remethylation to methionine is catalyzed by the methionine 
• I synthase (MTR) enzyme62 and links the folate cycle with the homocysteine 
metabolism [figure 6) MTR requires cobalamm as a cofactor and the resulting com­
plex, cbKDMTR, binds the methyl group of 5-methylTHF to form methylcbKllllMTR 
Upon transfer of the methyl group to homocysteine cbKDMTR is reformed, which can 
now again accept a new methyl group from 5-methylTHF CoblDalamm can also be 
oxidized to cob(ll)alamin, which results in an inactive cbl(ll)MTR complex Methionine 
22 
Figure 5 
Schematic overview of 
folate uptake and transport 
from the intestine, via blood, 
into the cell. 
THF tetrahydrofolate 
FR-a folate receptor alpha 
PCFT proton-coupled folate transporter 
RCF1 reduced folate carrier 
synthase reductase (MTRR) reactivates the cbl(ll)MTR complex by reductive meth-
ylation, using S-adenosylmethionine (AdoMetl as a methyl donor63. 
While the MTR enzyme is ubiquitously expressed, another homocysteine remeth-
ylation system, the betaine-homocysteine methyltransferase (BHMT), is mainly 
expressed in the liver and kidneys^. BHMT can remethylate homocysteine using 
a methyl group derived from betaine and is responsible for approximately 50% of 
homocysteine remethylation in the liver. 
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Figure 6 
Schematic representation of the folate cycles and homocysteine metabolism 
AdoHcy, S-adenosylhomocysteine; AdoMet, S-adenosylmethionine; AHCY, S-adenosylhomocysteme 
hydrolase; ATP. adenosine tr iphosphate; BHMT, betaine-homocysteine methyltransferase; CBS, cysta­
thionine ß-synthase; CTH, cystathionine γ-lyase; DHF, dihydrofolate; DHFR, dihydrofolate reductase; 
dUMP, deoxyuridine monophosphate; dTMP, deoxythymidine monophosphate; MAT, methionine-ad-
enosyltransferase; MTHFD, methylenetetrahydrofolate dehydrogenase / methenyltetrahydrofolate cy-
clohydrolase / formyltetrahydrofolate synthetase; MTHFR, methylenetetrahydrofolate reductase; MTR, 
methionine synthase; MTRR, methionine synthase reductase; SHMT, serine-hydroxymethyltransfer-
ase; THF, tetrahydrofolate; TYMS, thymidylate synthase. 
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Transmethylation 
3.2 Methionine adenosyltransferase (MAT) catalyzes the biosynthesis of Ado-Met from methionine and ATP65 Methionine adenosyltransferase is en-
coded by two genes that display a tissue specific expression pattern Methionine 
adenosyltransferase 1A is only expressed in adult liver, whereas methionine adeno-
syltransferase 2A is present in almost all tissues6667 AdoMet is one of the most im-
portant methyl donors in our body donating its methyl group to, for example, DNA, 
RNA and proteins By doing so S-adenosylhomocysteme (AdoHcy) is formed which 
is a potent inhibitor of transmethylation reactions AdoHcy hydrolase [SAHH) can 
hydrolyze AdoHcy to adenosine and homocysteine (figure 6] 
Transsulfuration 
3-3 Where homocysteine is retained during remethylation and transmethy-lation reactions, m the transsulfuration pathway homocysteine is irrever-
sibly degraded to cysteine by the action of two vitamin B6 dependent enzymes cysta-
thionine ß-synthase (CBS) and cystathionine γ-lyase (CTH) (figure 6) CBS catalyzes 
the condensation of homocysteine and serine to cystathionine and CTH subsequently 
catalyzes the hydrolysis of cystathionine to cysteine and a-ketobutyrate Although 
CBS is only expressed m the liver and kidneys, expression of CBS during early em-
bryogenesis has also been reported6 8 
4 Possible mechanisms underlying NTDs 
The observation that women who use vitamins containing folic acid penconceptio-
nally are at reduced risk for NTD affected pregnancies is one of the most promising 
clues to the causes of NTDs In the search for mechanisms underlying the beneficial 
effect of folic acid m relation to NTDs several mechanisms have been suggested and 
examined (figure 7) Two mechanisms that are hypothesized to play a role in NTD 
etiology are discussed in more detail below 
Methylation 
/ Λ The methylenetetrahydrofolate reductase (MTHFR) enzyme has a unique 
** function m that it regulates the availability of methyl groups for methyla­
tion reactions at the cost of purine and pynmidme synthesis The 677C>T variant 
in the MTHFR gene renders a less active thermolabile MTHFR enzyme69, resulting 
25 
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in elevated levels of 10-formylTHF and a decreased availability of 5-methylTHF in 
red blood cells70. The observations that the MTHFR 677TT genotype decreases the 
availability of 5-methylTHF for methylation69, results in a reduction of global DNA 
methylation7 1 7 2 and is a genetic risk factor for NTDs73 support the idea that DNA 
methylation plays an important role in NTD etiology. The observation that inactiva-
tion of the DNA methyltransferase DNMT3B disrupts de novo DNA methylation and 
causes multiple developmental defects including NTDs in mice, further underlines 
the importance of DNA methylation in relation to NTDs74. In addition, culturing rat 
embryos on low methionine resulted in NTDs and protein hypomethylation that was 
specific for proteins located in the neural tube, indicating that protein methylation 
also plays an essential role in proper neural tube closure30·75. 
Using a chick embryo model, our group recently tested the hypothesis that me­
thylation is crucial for proper neural tube closure38. Inhibition of both MAT and AHCY 
in our in vitro chick embryo model resulted in a widening of the anterior neuropore 
(ANP) and a decreased AdoMet/AdoHcy ratio, indicating an impaired methylation. 
Inhibition of MAT in cultured mouse embryos also decreased the AdoMet/AdoHcy 
ratio and these embryos also represented with cranial closure defects76. 
The data of all of these studies have resulted in the hypothesis that methylation 
is hampered in women that are pregnant with a NTD affected child and that folic 
acid supplementation prevents NTDs by donating methyl groups, hereby improving 
methylation5 4. 
Figure 7 
Schematic representation of factors that influence folate metabolism and 
methylation being the possible mechanism via which the folate metabolism 
is linked to NTD etiology. 
Environmental factors 
Diet 
Polare receptor autoantibodies 
Genetics 
-> Folate ^ ^ Neural 
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Folate receptor autoantibodies 
4 Q Another mechanism that has recently been proposed by Rothenberg et al. • ^ is the presence of autoantibodies directed against the folate receptor in the 
serum of women whose pregnancy is or was complicated by NTDs77. The autoanti­
bodies were shown to block the binding of folic acid to the folate receptors and inhi­
bited folic acid uptake by KB cells, a human epidermoid carcinoma cell line. An extra 
amount of folic acid could theoretically overcome this blockage and the presence 
of folate receptor autoantibodies may thus explain part of the preventive effect of 
penconceptional folic acid supplementation7 7. This study is promising however, the 
study population of Rothenberg's study was small and additional studies in larger 
populations are necessary to determine the exact role of folate receptor autoanti­
bodies in the etiology of NTDs. 
The mechanism by which folate receptors become self-antigens is not known. 
Rothenberg et al. speculated that, since NTD risk is increased after abortions and 
miscarriages, the exposure of epitopes of the folate receptor as a result of injury of 
reproductive tissues in combination with genetic factors may induce autoantibody 
formation7 7. It was also suggested that the production of folate receptor autoanti­
bodies could be induced by soluble folate binding proteins in human or bovine milk 
or by sensitization by unknown antigens with epitopes similar to that of the folate 
receptor78. Another possible explanation for the production of folate receptor auto­
antibodies could be a decreased Τ cell DNA methylation. It has been demonstrated 
that a decreased Τ cell DNA methylation results m the overexpression of several 
genes and that overexpression of these genes leads to autoreactivity in vitro and au­
toimmunity in vivo79·80. This possible explanation for the presence of folate receptor 
autoantibodies in women with a NTD affected pregnancy links an impaired methyla­
tion to the presence of folate receptor autoantibodies, two mechanisms that have 
both been suggested to underlie NTD etiology. 
5 Genetic variations and neural tube defects 
Since the observation that penconceptional folic acid supplementation reduces the 
risk of having a NTD affected pregnancy, many single nucleotide polymorphisms 
(SNPs] m genes encoding for enzymes involved m folate uptake, the folate cycle and 
the closely related homocysteine metabolism have been identified and examined in 
relation to NTDs. In this section, an overview of all SNPs that have been examined in 
relation to NTD risk is given. 
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5.1 Folate uptake 
Glutamate carboxypeptidase II 
5 Λ Λ Devlin et al reported thatthe 1561C>TSNPin theGCPII gene [His^75Tyr) • ' · ' leads to a reduced activity of the FGCP enzyme and subsequent de­
creased plasma folate levels and increased plasma Hey levels81 In contrast to these 
data, our group observed that the 1561C>T SNP results m increased plasma folate 
levels and we could not demonstrate an association between this SNP and NTD 
risk82 Other studies could not find an effect of the GCPII 1561C>T SNP on NTD risk 
or metabolite levels either8 3 8 6 It is worth mentioning that the supplemented form 
of folate, folic acid, is a synthetic monoglutamate and does not require FGCP to be 
absorbed The use of penconceptional folic acid supplementation could thus attenu­
ate possible effects of genetic variation in the GCPII gene 
Folate receptor α and β 
5 «| ry Folate mainly enters the cell via the FR-a The importance of FR-a is • ' • ^ " demonstrated by the observation that folate-bmdmg protein 1 (Folbpl, 
the mouse ortholog of human FR-a) nullizygosity is embryonic lethal in knockout 
mice8' In 1998, Barber et al conducted a study m search for molecular genetic 
variation within the FR-a gene among a group of newborns with spina bifida Using 
single-stranded conformation polymorphism (SSCP) analysis, dideoxy fingerprinting 
(ddF) and sequence analysis, they did not find any variation m the exons 3 through 
6, encoding for the mature protein8 8 Almost simultaneously, our group analyzed the 
total coding region including the intron-exon boundaries and the signal sequences 
of human FR-a and FR-ß m 39 spina bifida patients, 47 mothers with a spina bifida 
affected child and 10 controls and could not identify any variation either89 Recently, 
two SNPs in the 5 -UTR of the FR-a have been reported however, both with low 
prevalence lea 0 4% each]90 
0 Leary et al focused on the FR-ß instead of the FR-a and examined 5 SNPs in the 
FR-ß gene that were present in the public database Four of these SNPs were not 
identified m their study population However, they did confirm the presence of an 
A>T substitution m intron 1 with a high allele frequency, but no association with NTD 
risk was found" 
The coding regions of the FR-a and FR-ß do not show any variation Some variants 
have been identified in the untranslated regions of these two genes, but none of the 
variations identified so far has been associated with NTD risk Likely, the folate re-
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ceptor genes do not tolerate any variation m their coding regions and variants in the 
folate receptors may not be compatible with life This is supported by data from the 
Folbpl knockout mouse model9 7 
Reduced Folate Carrier 
5 Λ Λ An 80A>G substitution was identified m the RFC1 gene, changing a his-• ' · Ο tidme to an arginine [His27Arg)92 Shaw et al could not demonstrate an 
association between the RFC1 80A>G SNP and spina bifida risk m children, although 
they did observe a possible increase m spina bifida risk for children whose moth­
ers did not use folic acid penconceptionally93 De Marco et al identified the 80A>G 
SNP in the RFC1 gene as a risk factor for NTDs in both patients and mothers9 4 
A study in a Chinese population reported an increased NTD risk m patients with 
the 80GG genotype, especially when their mothers did not utilize folic acid supple­
ments'5 Other studies could not find an association between the RFC1 80A>G SNP 
and NTD r i s k 8 3 8 " 6 " , although one study demonstrated an association between the 
RFC1 80GG genotype and low red blood cell (RBC) folate8 3 In summary, the RFC1 
80A>G SNP may be a NTD risk factor, especially when maternal folate status is low, 
suggesting that sufficient folate can attenuate the effect of this polymorphism 
5.2 Folate cycles 
Methylenetetrahydrofolate dehydrogenase 
5 /> /• Our group analyzed the MTHFD1 gene m 117 NTD patients by SSCP • ^ · I analysis and identified a 1958G>A SNP, resulting in an ammo acid sub­
stitution of an arginine by a glutamme within the 10-formyltetrahydrofolate synthe­
tase domain of the MTHFD1 enzyme (Arg653Gln) This SNP had a similar frequency 
among NTD patients and controls and did not influence plasma Hey concentration1 0 0 
More recently this 1958G>A SNP has been associated with an increased maternal 
NTD risk, but not with an increased NTD risk in the patient, in two different Irish 
study populations1 0 1 1 0 2 In an Italian population, the MTHFDI 1958G>A SNP has been 
associated with NTD risk in both mothers and children1 0 3 
More studies on the MTHFDI 1958G>A SNP are necessary to determine the influ­
ence of this SNP on NTD risk 
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Thymidylate synthase 
5 Λ Λ A28-bp tandem repeat in the 5'UTR of the thymidylate synthase (TYMS) • ^ • ^ gene has been identified, typically containing two or three repeats104. 
The triple repeat results in increased TYMS gene expression, whereas the double 
repeat is associated with a decreased TYMS gene expression11"1,05. The repeat has 
been associated with decreased plasma folate and total plasma Hey concentrations 
in a Chinese population however106, no such effect was found m a Northwestern 
European population1 0 7. Two studies examined the association between the repeat 
and NTD risk; Volcik et al. showed the double repeat to be associated with NTD risk 
in infants, especially m non-Hispanic US whites1 0 8. Wilding et al. could not demon­
strate a significant association between the repeat and NTD risk in NTD cases and 
their parents109. 
A 6-bp deletion in the 3'-UTR has been suggested to play a role in TYMS mRNA 
stability and translation1 1 0 and the non-deleted genotype has been associated with 
increased NTD risk, only in non-Hispanic US whites1 0 8. The only study that examined 
the 6-bp deletion m relation to plasma Hey and folate levels, reported an associa­
tion between this TYMS variant and RBC folate levels and plasma Hey levels m non­
smoking individuals111. Based on these data, more studies on the relation between 
the TYMS variants and folate status and NTD risk are warranted. 
Dihydrofolate reductase 
5 Λ r\ All folic acid present in vitamin supplements and food fortification is • ^ « O unreduced and requires the action of DHFR before it can participate in 
cellular processes. 
Recently, a 19-bp deletion has been described within intron-1 of the DHFR gene, 
removing a potential SPI transcription factor-binding site, possibly affecting DHFR 
gene-expression112. In this study, the 19-bp deletion was shown to increase the risk 
of having a child with spina bifida112. These data warrant more studies on the asso­
ciation between the 19-bp deletion m the DHFR gene and NTD risk. 
Serine-Hydroxymethyltransferase 
5 r\ § In 2001, we conducted a study to identify genetic variation in both the • ^ • T " cytosolic and mitochondrial isoform of the SHMT gene m 70 NTD pa­
tients. Several SNPs were identified, of which the 1420C>T substitution in the cSH-
MT gene and the 4-bp deletion in the 3'-UTR of the mSHMT gene were common1 1 3. 
The 1420C>T SNP, changing a leucine into a phenylalanine (Leu474Phe] m the cy-
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tosolic protein, was not associated with NTD risk in mothers, although the 1420CC 
genotype resulted in elevated plasma Hey concentrations and decreased RBC and 
plasma folate levels in mothers. The 4-bp deletion in the 3'-UTR of the mSHMT gene 
did not influence NTD risk, nor plasma Hey and folate levels113. 
Other studies also looked at the U 2 0 O T 5NP in the cSHMT and demonstrated a 
possible protective effect of the Τ allele m mothers, although not significant9 6 '7. 
Studies by Geisel et al. and Relton et al. could not demonstrated a relation between 
the cSHMT U20C>T SNP and plasma Hey and RBC folate'6·114. In conclusion, the 




Λ — In collaboration with researchers at Montreal Children's Hospital, our 
• Z . Q group described the 677C>T (Ala226Val) SNP in the MTHFR gene, re­
sulting in a mildly dysfunctional "thermolabile" MTHFR enzyme, and demonstrated 
an association between the 677TT genotype and elevated plasma Hey levels6'. In 
the same year, we reported an increase in spina bifida risk for both mothers and 
children with the MTHFR 677TT genotype and hereby identified the first genetic risk 
factor for spina bifida73. 
After the identification of the MTHFR 677C>T SNP. many studies investigated this 
SNP in relation to NTD risk and some results were contradictory and non-conclu­
sive, m part because of the considerable variation in MTHFR 677C>T allele frequency 
among different geographical areas and ethnicities1 1 5 1 1 8. 
In 2000 Botto and Yang conducted a meta-analysis on the MTHFR 677C>T SNP in 
relation to NTD risk1 1 5. They reported a 2-fold increase in risk for being a mother 
of a NTD affected child (OR:2.0; 95%CI:1.5-2.8) and a 1.8-fold increased NTD risk 
(OR:1.8; 95%CI:1.4-2.2) for infants when having the MTHFR 677TT genotype. Re­
cently, our group also conducted a meta-analysis on the MTHFR 677C>T SNP in re­
lation to NTD risk". This meta-analysis demonstrated that mothers with the MTHFR 
677TT genotype had a 60% increased risk of delivering a child with a NTD (ORI.6; 
95%CI:1.3-2.0], whereas the MTHFR 677TT genotype was associated with a 90% 
increased NTD risk in children (OR:1.9; 95%CI:1.6-2.2F. In summary, the MTHFR 
677TT genotype is a genetic risk factor for NTDs in both NTD patients and their 
mothers. 
A second SNP in the MTHFR gene involves the substitution of an adenine by a cyto-
sine on position 1298 (1298A>C), leading to an ammo acid change of a glutamate into 
an alanine (Gln433Ala)119. This SNP has also been associated with a decreased MTH­
FR enzyme activity, although not as pronounced as the MTHFR 677C>T SNP11511'12«. 
To date, only one study121 out of many has found an association between the MTHFR 
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1298A>C SNP and NTD risk, whereas the SNP does not seem to influence Hey and 
folate levels m plasma11 'uo m 125 The MTHFR 1298A>C SNP is not likely to be a risk 
factor for NTDs 
5-3 Homocysteine metabolism 
Methionine synthase 
5.3.1 Sequencing analysis of the coding region of the MTR gene by our group 
revealed a 2756A>G SNP, changing an aspartic acid residue that is believed to be 
part of a helix involved m co-factor binding, to a glycine (Asp919Gly]126 Several stud-
ies examined the MTR 2756A>G SNP in relation to NTDs Some studies associated 
the G allele with an increased maternal NTD risk127, an increased NTD risk in the 
child128129, or m both mother and child130 However, other studies could not demon-
strate any association between the MTR SNP and NTD risk12112'131 133 and one study 
associated the MTR 2756GG genotype even with a decreased NTD risk m patients1311 
Plasma Hey levels have been reported to be increased for the MTR 2756AA gen-
otype135136, although this relation was not always significant137138 or even not pre-
sent126139"0 The MTR 2756AA genotype does not seem to influence plasma folate 
levels135138140, although one study reported increased plasma folate levels for the 
MTR 2756GG genotype137 
The associations between the MTR 2756A>G SNP and plasma Hey and plasma folate 
concentrations as well as the relation between this polymorphism and NTD risk are 
non-conclusive If there is a relation between the MTR 2756A>G SNP and NTD risk, it 
is at the most a rather moderate association 
Methionine synthase reductase 
5 Q Q In 1999, Wilson et al described a common variant m the FMN-bmding • O · ^ domain of the gene encoding for the MTRR enzyme the 66A>G SNP, 
leading to an ammo acid substitution of an isoleucme by a methionine (lle22Met)u1 
They reported an increased NTD risk for both mothers and patients with the MTRR 
66GG genotype however, only when plasma vitamin B12 concentration was lowu1 
Later, a study by Zhu et al reported the MTRR 66AG/GG genotype to be associated 
with an increase m NTD risk for both mothers and patients128 In a Polish study the 
association between the MTRR 66GG genotype and NTD risk was confined to lumbo-
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sacral NTDsU 2. In other studies, the MTRR 66GG genotype was not significantly asso­
ciated with NTD risk in mothers and offspring130·132·141·"13. In contrast to the previously 
discussed data, Relton et al. designated the A allele as risk factor for NTDs however, 
the MTRR genotype distribution was not in Hardy-Weinberg equil ibrium9 6 9 7. Using a 
transmission disequilibrium test (TOT), Doolin et al. also reported the A allele to be 
a risk factor for NTDs, only in mothers1 2 7. 
Studies of Olteanu et al. showed that the substitution of an isoleucine by a methio­
nine at position 22 m the MTRR enzyme results in a less efficient repair of the MTR, 
possibly due to a reduced affinity for this enzyme1"1 4 5. The MTRR 66A>G SNP has 
been associated with elevated plasma Hey levels146147, although most studies could 
not find an effect of the MTRR SNP on plasma Hey1 3 8 1 4 0 1 4 1 1 4 8 1 4 9. 
In summary, the MTRR 66GG genotype seems to be a NTD risk factor m mothers, 
without altering plasma Hey concentration. 
Transcobalamin 
5 r\ Λ In plasma 80% of total vitamin B12 is bound to holo-haptocorrm and is • Ο · 0 not available for cellular uptake. The remaining 20% is bound to holo-
transcobalamin (TC) that transports vitamin B12 into the cell, where it is used as a 
cofactor for Hey remethylation and L-methylmalonyl CoA conversion. We reported a 
decreased TC-saturation with vitamin B12 m mothers with NTD offspring1 5 0. Later, 
our group identified five sequence variants in the TC gene of which the 776C>G SNP 
(Pro259Arg) has been described before151. We analyzed the frequency of each SNP 
m a population consisting out of mothers of NTD affected children and controls1 5 2. 
None of the SNPs was associated with NTD risk or with plasma Hey concentration, 
although a trend was observed for the 776C>G SNP with elevated Hey levels. The 
776C>G SNP was associated with low total-TC, holo-TC and apo-TC levels and with 
a decreased holo-TC/total-TC ratio that could be explained by a reduced binding of 
vitamin B12 to TC152. The effect of this variant on TC level and saturation has been 
confirmed m a different study population153. 
Other studies also investigated the relation between genetic variants in the TC gene 
and NTD risk. Pietrzyk et al. demonstrated the 776GG genotype to be associated with 
an increase in maternal NTD risk1 5 4 whereas, studies by Gueant-Rodnguez et al. and 
Swanson et al. could not find such an effect of the 776C>G SNP or other SNPs in 
the TC gene on NTD risk1 5 5 1 5 6. Studies that investigated the relation between the TC 
776C>G SNP and plasma Hey concentration did not show an association between the 
this SNP and plasma Hey levels1 1 4 1 5 7 1 5 9. In summary, the TC 776C>G SNP does not 
seem to be a NTD risk factor. 
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Betaine-Homocysteine Methyltransferase 
5 r\ ι Our group analyzed the BHMT gene and identified the 595G>A SNP • 0 » ^ f (Gly199Ser), the 716G>A (Arg239Gln] SNP that was previously re­
ported1 6 0 and the 1218G>T (GlnAOóHis) SNP, but none of them was associated with 
plasma Hey levels161. Weisberg et al did not find a relation between the 716G>A SNP 
and plasma Hey concentration either162. The 716G>A SNP has been associated with 
a decrease in NTD risk in both children and mothers163, although a recent study by 
Zhu et al. could not demonstrate a protective effect of the 716AA genotype in NTD 
patients16'. 
In mouse embryos, BHMT is not expressed until neural tube closure has almost 
completed165, which makes it less likely that the BHMT 716G>A SNP wil l be a risk fac-
tor of NTDs in the fetus. Since the BHMT enzyme is responsible for 50% of the liver 
Hey remethylation, variation in the maternal BHMT gene could affect maternal Hey 
metabolism, hereby influencing the risk of having NTD affected offspring. 
Cystathionine ß-synthase 
5 r\ r~ Although CBS is only expressed in liver and kidneys, Quere et al. re-• O · O ported CBS to be expressed during early embryogenesis68 and varia-
tion in the CBS gene may thus influence embryogenesis. 
The 68-bp insertion (844ins68) and the 31-bp variable tandem repeat (31-bp VNTR] 
in the CBS gene are the most frequently studied variations in relation to NTDs. The 
844ins68 has not been associated with NTD risk in children or mothers130131,6616B, 
although the studies by Akar et al. and Richter et al. show a trend towards a protec-
tive effect of the 68-bp insertion168169. A possible gene-gene interaction between the 
MTHFR 677C>T polymorphism and the CBS 844ins68 was also examined in relation 
to NTDs. Except for one study in children170, no such association could be demon-
strated131166168. In conclusion, the CBS 84Ains68 does not seem to be a NTD risk 
factor. 
The 31 -bp VNTR has been described first by Kraus et al. and has been further char-
acterized by our laboratory171172. We showed that the 31-bp VNTR results in alterna-
tive spicing and a subsequent decrease in enzyme activity that is negatively cor-
related with the number of repeat units. The number of repeat units was positively 
associated with plasma Hey concentrations172. In a later study, we also demonstrated 
the 18/18 VNTR genotype to be associated with elevated plasma Hey levels compared 
to the 17/18 and 18/19 VNTR genotypes173. In addition, a study by Yang et al. reported 
plasma Hey levels to be decreased in individuals with the 16/17 and 17/18 VNTR 
genotype, compared to the 17/17 VNTR genotype174. However, the 31-bp VNTR does 
not influence the risk of NTDs173. 
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6 Objectives and outline of this thesis 
Objectives 
6.1 The general aim of this thesis is to identify mechanisms underlying NTDs In order to elucidate these mechanisms different approaches are used 
1 A candidate gene approach is used to identify associations between SNPs in genes 
encoding enzymes that play a role m the folate cycle and the closely related homo-
cysteine metabolism and spina bifida risk 
2 The role of methylation m NTD etiology is examined by 
a) Determining global DNA methylation status m spina bifida patients and pediatric 
controls 
b) Determining the effect of methylation inhibition on gene expression m a chick em-
bryo model m order to identify new genes involved m the etiology of NTDs 
Outline 
6.2 Part 1 In Part 1 of this thesis studies on the association between known genetic variants and spina bifida risk that have been performed m a Dutch 
study population of spina bifida patients and their parents are described Chapter 2 
describes the effect of two genetic variants m the DHFR gene on DHFR gene expres-
sion levels and spina bifida risk. In Chapter 3 the association between the 1958G>A 
SNP in the MTHFD1 gene and spina bifida risk is studied and m Chapter 4 the as-
sociation between a SNP in the MTRR gene and spina bifida risk is examined by 
conduc-tmg a case-control study, a transmission disequilibrium test (TDT) and a 
meta-analysis A possible interaction between the N0S3 894G>T SNP and the MTHFR 
677C>T SNP or elevated plasma homocysteine concentration in relation to spina bi-
fida risk, is demonstrated in Chapter 5 
Part 2 In Part 2 of this thesis the role of methylation in NTD etiology is examined In 
Chapter 6 differences m global DNA methylation between spina bifida patients and 
pediatric controls are discussed Chapter 7 describes the identification of genes that 
are differentially expressed between control chick embryos and chick embryos that 
have been treated with the methylation inhibitor periodate oxidized adenosine (Adox) 
and exhibit neural tube closure defects, using microarray experiments 
In Chapter 8 all the studies presented m this thesis are discussed and directions for 
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» ι . . The dihydrofolate reductase (DHFR) enzyme is important for folate 
M U b l l d L l availability, folate turnover and DNA synthesis. The 19-bp deletion 
in intron-1 of DHFR has been associated with the risk of having spina bifida affected 
offspring, supposedly by changing DHFR gene expression. A 9-bp repeat in exon 1 
of the mutS homolog 3 (M5H3) gene was recently demonstrated to be also located 
in the 5'UTR of DHFR and may possibly affect DHFR gene expression as well. We 
examined the association between these DHFR variants and spina bifida risk and 
investigated their effect on DHFR expression. Our study population, consisting of 121 
mothers of a spina bifida affected child, 109 spina bifida patients, 292 control women 
and 234 pediatric controls was screened for the DHFR 19-bp deletion and the DHFR 
9-bp repeat. DHFR gene expression was measured in 66 spina bifida patients, using 
real-time PCR analysis. In this study population, the DHFR 19-bp del/del genotype 
was not associated with spina bifida risk in mothers and children (OR:0.8; 95%CI:0.4-
1.5 and 0R:1.2; 95%CI:0.6-2.2, respectively) and both the WT/del and the del/del 
genotype did not affect DHFR expression relative to the WT/WT genotype [relative ex­
pression^.89, p=0.46 and relative expression^.26, ρ=0.2Λ, respectively). The DHFR 
9-bp repeat was not associated with spina bifida risk in mothers and children. DHFR 
expression of the 6/6 allele was 73% increased compared to the 3/3 allele, although 
not significantly (relative expression^.73, p=0.09). We did not find evidence for an 
effect of the DHFR 19-bp deletion or 9-bp repeat on spina bifida risk in mothers 
and children. An effect of the 6/6 repeat genotype on DHFR expression cannot be 
ruled out. 
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• . ι . · The Β vitamin folate has been associated with a variety of 
11 I L I U U U l U U 11 complications during pregnancy e.g. orofacial clefts1 7 5, con­
genital heart defects176 and neural tube defects (NTDs)52. The most obvious and ex­
tensively studied birth defects m relation to folate are NTDs. Nowadays it is well 
established that periconceptional folate supplementation reduces the occurrence 
and recurrence risk of NTDs by 50-70%4 t U 7 5 2. The search for the molecular genetic 
basis of this beneficial effect of folic acid however continues54. 
DHFR reduces dihydrofolate (DHF) that is formed during thymidylate (dTMP) syn­
thesis back into tetrahydrofolate (THF) and hereby stimulates folate turnover, the 
production of dTMPs and hence DNA synthesis. These processes are all essential 
for rapid cell growth and division. An adequate folate turnover is also important for 
proper methylation of DNA, RNA and proteins, since folate donates its methyl group 
to homocysteine that is converted into S-adenosylmethionme after remethylation to 
methionine. S-Adenosylmethionine is one of the most important methyl donors in 
the body. In addition, DHFR reduces folic acid present in vitamin supplements and 
food fortification so that it becomes metabolically active. The importance of DHFR is 
further illustrated by the observation that the coding region of the DHFR gene har­
bors no variation in 20 individuals whose DHFR gene was sequenced177. 
Recently, Johnson et al. described a 19-bp deletion in intron-1 of the DHFR gene and 
reported an association between this deletion and an increased risk of having a spina 
bifida affected child in a population consisting of 61 spina bifida patients, 50 mothers 
and 46 fathers of a spina bifida affected child and 219 controls [OR:2.0; 95%CI:0.94-
4.29]112. They hypothesize that the deletion removes a possible transcription factor 
binding site for Spi , thereby decreasing DHFR expression. A 9-bp repeat in exon 1 
of the mutS homolog 3 (MSH3) gene identified by Nakajima et al.1 7 8 was recently de­
scribed to be also located in the 5' untranslated region [DTR) of DHFR and therefore 
might interfere with DHFR expression177. 
In this study we examined a possible association between the 19-bp deletion and the 
9-bp repeat m the DHFR gene and the risk of spina bifida m 121 mothers of a spina 
bifida affected child, 292 control women, 109 spina bifida patients and 234 pediatric 
controls using a case-control design. Furthermore, we investigated the effect of the 
DHFR 19-bp deletion and the DHFR 9-bp repeat on DHFR expression levels in cul­
tured lymphoblasts of 66 spina bifida patients using real-time quantitative PCR. 
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Materials and Methods 
Q t u H v n n m i l a t i n n "'"'ie s t u c ' y population was recruited m collaboration 
* H r W |th the BOSK and was extended by a group from the 
Pediatric Neurology Department of the Radboud University Nijmegen Medical Cen­
ter. The BOSK is a Dutch society for patients with central nervous system defects 
and their parents and is a national organization. Spina bifida patients recruited from 
the Radboud University Nijmegen Medical Center represent a general spina bifida 
population from the region. The study group included 109 spina bifida patients (61 
girls and 48 boys, mean age 16.Λ +/- 11.3), their mothers (n=121, mean age Λ2.89 +/-
10.89] and their fathers (n=103, mean age ΛΛ.9 +/- 10.2]U 9. 
The control group consisted of volunteers recruited from a general practice in The 
Hague. Two thousand eight hundred and twelve individuals aged 20-90 years, were 
invited to participate in a health survey of risk factors for cardiovascular disease. Five 
hundred and thirty-two people agreed to participate and the first 500 were included 
in the study. In the present study we only included the 292 women out of this control 
group (mean age 50.55 +/- 13.Λ7]. The individuals are unrelated and have no history 
of spina bifida and did not have a spina bifida affected child1 7 '. The constitution of the 
pediatric control group has been described previously190. Briefly, the control group 
consisted of 234 children (119 girls and 115 boys, mean age 8.A +/- 6.4). The children 
of secondary school age were healthy volunteers and the younger children were, for 
ethical reasons, recruited in a hospital setting. Exclusion criteria were overt liver and 
renal dysfunction, hormonal therapy, neoplastic disease and closure defects such as 
cleft lip and spina bifida. The local medical ethics committee approved the study. For 
this study, DNA was available of 102 spina bifida patients, 116 mothers, 101 fathers, 
265 control women and 211 pediatric controls. 
Laboratory determinations Plasma total homocysteine concen­
tration was measured m EDTA plasma 
by HPLC and fluorescence detection, as previously described by Te Poele-Pothoff et 
al.1 8 '. Plasma folate and red blood cell (RBC) folate levels were determined using 
the Dualcount Solid Phase Boil Radio assay (Diagnostic Product Corporation, Los 
Angeles, CA). 
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PCR amplification and 
, . 19-bp deletion The DHFR 19-bp deletion was 
g e n o t y p e d e t e r m i n a t i o n screened for as previously described"
2177. 
In brief, amplification of genomic DNA was carried out using the following primers: 
Forward 1 (5-CCACGGTCGGGGTACCTGGG-3'). Forward 2 (5'-ACGGTCGGG GTGGCC-
GACTC-3') and a reverse primer (5'-AAAAGGGGAATCCAGTCGG-3']. PCR products 
were analyzed on a 3% agarose gel, stained with ethidium bromide and visualized 
by UV light. On each gel, samples with a sequence confirmed DHFR 19-bp genotype 
were run as positive controls. 
9-bp repeat The DHFR 9-bp repeat was screened for as previously described 
by our group1 7 7. Briefly, genomic DNA was amplified with the forward primer (5'-
GCCCAGTCCCAGACAGAAC-3') and the reverse primer (5'- GAGCCGATTCTTCCAGTC-
TAC-3']. PCR products were run on a 3% agarose gel for at least 3 hours, stained with 
ethidium bromide and visualized with UV light. On each gel samples with a sequence 
confirmed DHFR 9-bp repeat genotype were run as positive controls. To confirm the 
genotypes identified by agarose gel, bands from some samples were excised from 
the gel. The PCR products were purified using the gel extraction kit from Qiagen and 
PCR products were subsequently sequenced to verify the genotype of the excised 
alleles. 
Table 1 
Primers used for QPCR analysis 

















Ρ Γ Ρ ί Ω Ρ Γ Ρ ΐ Lymphoblast cell lines were established from heparin blood 
from each patient using Epstein-Barr virus. Cell lines were cul­
tured on RPMI serum with Fetal Calf Serum (FCS). RNA was isolated from the cul­
tured Iymphoblasts as described previously182 and was DNAse treated to eliminate 
possible genomic DNA contamination. The DNAse treated RNA was subsequently 
reverse transcribed to cDNA by standard techniques, using random primers (Invitro-
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gen, Breda, The Netherlands! in a final reaction volume of 20 m L 
The DHFR gene has many pseudogenes. All DHFR pseudogene sequences present in 
the GenBank were aligned with the DHFR sequence and primers were developed in 
such a way that most of the DHFR pseudogenes were not amplified. QPCR products 
were also sequenced to check for co-amplification of pseudogenes. QPCR experi­
ments were carried out in a total volume of 50 μ ι containing: 2μΙ_ of k times diluted 
cDNA, 1 μΙ_ 20x sybrgreen (Molecular Probes), 200 nM of forward and reverse prim­
ers (table 1] (Biolegio BV, Maiden, The Netherlands), 200 mM dNTPs [Invitrogen, 
Breda, The Netherlands), 1x AmpliTaq Gold amplification buffer, 5 mM MgCl2 and 1 
U AmpliTaq Gold DNA polymerase (Applied Biosystems, Nieuwerkerk a/d Ijssel, The 
Netherlands). QPCR conditions were: initial denaturation at 95°Cfor 10 minutes, fol­
lowed by 35 cycles of: 30s at 95°C, 30s at 60°C and 30s at 72°C. After amplification, 
a melting curve was acquired by heating for 3 minutes at 950C, cooling to 25°C and 
heating again to 95°C with temperature intervals of 1 °C per 20s. Samples were run 
in duplicate on the Icycler iQ real-time PCR detection system (Biorad, Veenendaal, 
The Netherlands) and fluorescence was measured during each annealing step. 
Expression levels of DHFR were normalized to the reference genes ß-2-microglobu-
line (B2M) and porphobilinogen deaminase (PBGD) by comparative quantification, 
using the AÄCT method
183. For each sample, the ACT was calculated (CT DHFR - CT 
J. The mean relative expression was calculated as 2 AACT (AACT = ACT - ACT , ,). 
ref Γ Τ Τ Τ control 
The geNorm software was applied to combine both the results of B2M and PBGD to 
obtain a more accurate normalization1 8 4. 
Table 2 
DHFR 19-bp deletion genotype distribution 
and unadjusted odds ratios in mothers of a 
spina bifida affected child and control women 
DHFR 19-bp deletion Mothers (n=115) Control women |n=2U) OR |95%CI) 
WT/WT 39(33.9) 84 (34.4) 1a 
WT/del 57(49.6) 109(44.7) 1.1(0.7-1.9) 
del/del 19(16.5) 51(20.9) 0.8(0.4-1.5) 
Number of persons and percentage (%] are depicted 
a Reference group 
Statistical analysis Odds ratios (ORs) and their 95% confidence inter­
vals (CI) were calculated by means of logistic re­
gression analysis. ORs were not adjusted. 
The influence of the DHFR 19-bp deletion and the DHFR 9-bp repeat on plasma folate 
and RBC folate concentration and plasma homocysteine concentration was studied 
by means of linear regression analysis. Since plasma folate and RBC folate con-
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centrations and plasma homocysteine concentrations are positively skewed, these 
variables were logarithmically transformed prior to linear regression analysis. 
For the DHFR 19-bp deletion all genotypes were considered separately m both the 
logistic and linear regression models. For the DHFR 9-bp repeat only the most com-
mon genotypes (frequency > 5%) were included in the logistic and linear regression 
models. 
Deviation from Hardy-Wemberg equilibrium was calculated to assess the accuracy 
of the genotypmg assay. 
The power of the case-control study was calculated, using the Genetic Power Cal-
culator185. Al l tests were performed using SPSS software package version 12.0.1. 
Statistical significance was accepted at a two-tailed p<0.05 or a 95% CI of an odds 
ratio that did not include 1.0. 
Table 3 
DHFR 19-bp delelion genotype distribution and 
unadjusted odd ratios in spina bifida patients 
and pediatric controls 








99 (47 6) 
37(17.8] 
0 8(0 4-1 4) 
1 2(0 6-2.2) 
Number of persons and percentage [%) are depicted 
3 Reference group 
Results 
Case-control study 19-bp deletion Genotypmg for the DHFR 19-bp deletion was performed successfully in 115 moth-
ers and in 244 control women and the genotype distribution was in Hardy-Wemberg 
equilibrium (p=0.16). The study had a power of 57% to detect a twofold increase in 
risk of having a child with a spina bifida. Table 2 demonstrates that the 19-bp dele-
tion in the DHFR gene does not influence maternal spina bifida risk in this study 
population (table 2). 
Using linear regression analyses we examined the influence of the DHFR 19-
bp deletion on plasma and RBC folate concentrations and plasma homocyste-
ine concentrations. The DHFR 19-bp deletion had no effect on plasma folate and 
plasma homocysteine concentrations (data not shown). The WT/del and del/del 
genotypes showed a trend towards lower RBC folate levels compared to the WT/ 
WT genotype (p for trend=0 03], however this effect was confined to the mothers 
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of a spina bifida affected child. 
The DHFR 19-bp deletion genotype could be determined in 101 spina bifida patients 
and 208 pediatric controls and the genotype distribution was in Hardy-Weinberg 
equilibrium [p=0.77]. The power to detect a twofold increased spina bifida risk m 
children was 5 1 % . As shown in table 3, the 19-bp deletion m the DHFR gene did not 
influence the risk of spina bifida m children (table 3). 
Plasma folate concentrations were not affected by the DHFR 19-bp deletion geno­
type. In the pediatric controls, the del/del genotype was associated with a 17% de­
cline (95%CI: -30% to -3%) in plasma homocysteine concentration compared to the 
WT/WT genotype. This effect could not be observed in the spina bifida patients. Data 
on RBC folate concentrations in children was not available. 
Table A 
Genotype distr ibution and unadjusted odd ratios for the 
most common DHFR 9-bp repeat genotypes in mothers 
of a spina bifida affected child and control women 
DHFR 9-bp repeat Mothers |n=109) Control women (n=234) OR (95%CI) 
3/3 7(6.1] 22(9.1) 1a 
3/6 Α6[ΜΛ} 69(28.4) 2.1(0.8-5.3) 
3/7 5(4.4) 13(5.3) 1.2(0.3-4 6) 
6/6 40(35.1) 104(42.8) 1.2(0.5-3.1) 
6/7 11(9.6) 26(10.7) 1.3(0.4-4.0) 
Number of persons and percenlage l%] are depicted 
a Reference group 
5'UTR 9-bp repeat Genotypinq for the DHFR 9-bp repeat was successfully performed 
in 114 mothers of a spina bifida affected child and 243 control women. The presence 
of a variety of repeat alleles resulted in the identification of 12 different genotypes 
of which only the most common genotypes (frequency > 5%) were included in our 
statistical analyses. In our study population, the 3/3, 3/6, 3/7, 6/6 and 6/7 genotypes 
were most frequently observed. Less common genotypes were the 3/5, 3/8, 4/7, 5/6, 
6/8, 7/7 and 7/8 genotypes. More information on repeat location and repeat sequence 
can be found in our recent publication1 7 7. As shown in table 4 the most common 
DHFR 9-bp repeat genotypes did not have an effect on maternal spina bifida risk, ex­
cept for the 3/6 genotype increasing spina bifida risk about twofold relative to the 3/3 
10R:2.1; 95%CI:0.8-5.3) and 6/6 (OR:1.7; 95%CI:1.0-2.9) genotypes. Plasma and RBC 
folate concentrations and plasma homocysteine concentrations were not influenced 
by the DHFR 9-bp repeat (data not shown). 
Ninety-five spina bifida patients and 209 pediatric controls could be genotyped for 
the DHFR 9-bp repeat. Genotype frequencies and odds ratios for the most common 
DHFR 9-bp repeat genotypes in children are depicted in table 5. The 6/7 genotype 
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was associated with a fourfold increased risk of spina bifida relative to both the 3/3 
genotype |OR:4.5; 95%CI:1.0-19.1) and the 6/6 genotype (OR:4.0; 95%CI:1.1-U.5). 
The DHFR 9-bp repeat did not influence plasma folate and plasma homocysteine 
concentrations (data not shown). 
Real-time quantitative 
D T D ί η Ο Γ Ο ί There were no known DHFR pseudogenes co-amplified during 
r L K l U r L K J Q p C R a n a Î y S e s p r o m 6 6 S p j n a b i f j d a patients RNA was pres-
ent and QPCR analyses were performed. QPCR assays for B2M, PBGD and DHFR 
were optimized to obtain linear and efficient standard curves. Figure 9 demonstrates 
that spina bifida patients with the DHFR 6/6 genotype (n=32) tended to have a 73% 
increased DHFR expression compared to spina bifida patients with the DHFR 3/3 
genotype (n=5) (fold=1.73, p=0.09). DHFR gene expression m spina bifida patients 
with the 3/6 genotype (n=16) did not differ from DHFR gene expression in spina bifida 
patients with the 3/3 genotype (fold=1 Λ2, p=0.24, data not shown). We only examined 
the gene expression levels of patients with the 3/3, 3/6 and 6/6 genotypes, because 
the other DHFR repeat genotypes were not or only once present. 
No differences m DHFR expression could be detected between spina bifida patients 
with the DHFR del/del genotype |n=111 and spina bifida patients with the DHFR WT/ 
WT genotype [n=2A) (fold=1.26, ρ=0.2Λ, figure 9) or between spina bifida patients 
with the WT/del genotype [n=24] and spina bifida patients with the WT/WT genotype 
(fold=0.89, p=CU6, data not shown). 
Table 5 
Genotype distr ibution and unadjusted odd ratios 
for the most common DHFR 9-bp repeat genotypes 
in spina bifida patients and pediatric controls 








28 (29 5] 
2(2.1] 








1 0(0 4-2.5] 
0 9(0 1-5.0] 
1 1 (0 5-2.6] 
45(1 0-19.1) 
Number of persons and percentage [%] are depicted 
0 Reference group 
Discussion 
In our study population the DHFR del/del genotype was not associated with spina 
bifida risk in mothers and in children and had no effect on DHFR expression. 
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Johnson et al. demonstrated a twofold increased risk of having a spina bifida af-
fected child for the DHFR del/del genotype relative to the DHFR WT/del and WT/ 
WT genotypes (OR:2.0; 95%CI;0.9-^.3l and suggested that the deletion of a possible 
Spi transcription factor binding site, and hence decreased DHFR expression levels, 
could explain the observed effect of the DHFR 19-bp deletion on maternal spina bi-
fida risk"2. Although we did not observe an effect of the DHFR del/del genotype on 
spina bifida risk, we wanted to test this hypothesis of Johnson et al. and examined 
DHFR expression in 66 spina bifida patients. No changes in DHFR expression levels 
were observed among the different DHFR 19-bp deletion genotypes. The finding of 
Noè et al. that removing all introns does not affect DHFR mRNA expression levels in 
hamster cellines further supports our finding that the deletion of 19-bp in intron-1 
of the DHFR gene does not affect DHFR expression levels186. 
Figure 8 
Normalized DHFR gene expression (and 95%CI] 
for spina bifida patients with the DHFR 9-bp 6/6 
genotype rotative to spina bifida patients with the 
DHFR 9-bp 3/3 genotype 
A possible explanation for the difference in the observed effect of the DHFR 19-bp 
deletion on spina bifida risk between our study and the study of Johnson et al. could 
be the difference in study population. The study population of Johnson et al. consists 
of families with two or more individuals affected with spina bifida, whereas our study 
population consists of unrelated spina bifida cases. As they mention, families with 
two or more spina bifida patients may differ from single case families in ways we do 
not understand yet112. 
In a previous study of our group we examined the effect of the DHFR 19-bp deletion 
on plasma homocysteine concentration177. In that study we demonstrated a signifi-
cant 1Λ.4% decrease in plasma homocysteine concentration for the DHFR del/del 
genotype relative to the WT/WT genotype (95%CI: -23.4% to -4.5%). In the current 
study we used a subset of the study population from our previous study177, namely 
only the control women. This could explain the finding that in the present study the 
DHFR 19-bp deletion does not affect plasma homocysteine concentration. The fact 
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that the DHFR del/del genotype also decreased plasma homocysteine concentration 
in the pediatric control group supports the data of our previous study177. 
In the case mothers there was a trend towards lower RBC folate concentration for 
the DHFR WT/del and del/del genotypes relative to the DHFR WT/WT genotype. How-
ever, this effect of the DHFR 19-bp deletion was confined to the case mothers, in-
dicating that this may be a chance finding and not an effect of the genetic variant 
itself. 
A 9-bp repeat in exon 1 of the MSH3 gene identified by Nakajima et al.178 was recently 
described to be also located in the 5'UTR of the DHFR gene by our group177. To our 
knowledge, this is the first time that the DHFR 9-bp repeat is examined in relation 
to spina bifida risk. Because of the large variety in genotypes, statistical analyses 
for the DHFR 9-bp repeat were complicated. Therefore we decided to analyze only 
those genotypes that were relatively frequent in our population (> 5%). In mothers, 
the DHFR 9-bp repeat was not associated with spina bifida risk, except for the 3/6 
genotype that might increase the risk of having spina bifida affected offspring 2 
times compared to the 3/3 genotype (0R:2.1; 95%CI:0.8-5.3l. Based on the possible 
effect of the heterozygous DHFR 3/6 genotype on spina bifida risk, we expected an 
increased risk of having a spina bifida affected child when having the homozygous 
DHFR 6/6 genotype. This was not the case and therefore the observation that the 
DHFR 3/6 genotype increases maternal spina bifida risk is likely a chance finding 
possibly due to the small study population. 
2 - 5 - , 
Normalized 
DHFR 
expression - _ 
Figure 9 
Normalized DHFR gene expression land 95%CI| 
tor spina bifida patients with the DHFR 19-bp 
del/del genotype relative to spina bifida patients 
with the DHFR 19-bp WT/WT genotype 
H WT / WT 
• del/del 
In children, only the 6/7 genotype was associated with spina bifida, increasing the 
risk about U times relative to the DHFR 3/3 and 6/6 genotypes. However, the 95%Cls 
are broad and only few spina bifida patients have the DHFR 6/7 genotype. The effect 
of the 6/7 genotype on spina bifida risk is therefore probably a spurious result. 
Because the DHFR 9-bp repeat is located in the 5'UTR of the DHFR gene, the repeat 
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might affect DHFR gene expression. DHFR expression was examined in 66 spina bi­
fida patients of whom RNA was present. The DHFR 6/6 genotype tended to increase 
DHFR gene expression by 73% compared to the 3/3 genotype. An increased DHFR 
gene expression may result in increased DHFR protein availability however, the ef­
fect of the 6/6 genotype on DHFR gene expression was not translated into an effect 
on plasma folate and plasma homocysteine levels or spina bifida risk. Because of 
the large number of different genotypes, it would be very useful to examine the influ­
ence of the DHFR 9-bp repeat on DHFR expression and spina bifida risk in a larger 
population. 
It also would be of additional value to examine the influence of the DHFR 19-bp dele­
tion and the DHFR 9-bp repeat on DHFR expression in healthy individuals We now 
looked at DHFR expression levels in spina bifida patients, because RNA from healthy 
individuals was not present. Taking into account that spina bifida has a multifacto­
rial etiology, these children are likely to have multiple spina bifida risk factors. It is 
possible that these other risk factors may influence folate metabolism and/or DHFR 
expression independent from the DHFR 19-bp deletion and 9-bp repeat. 
In this study, the DHFR 19-bp deletion was not associated with spina bifida risk in 
mothers and children and did not affect DHFR expression. The DHFR 9-bp repeat 
had no effect on spina bifida risk, but an effect of the DHFR 6/6 genotype on DHFR 
expression cannot be ruled out. 
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Α Ι . . The MTHFDl 1958G>A SNP has recently been associated with neu-
M U o l l a L . 1 r a ^ t u ^ e defect (NTD) risk. In this study we examined the possible 
association between the MTHFDl 1958G>ASNP and spina bifida risk ma Dutch pop­
ulation consisting of 109 spina bifida patients, 121 mothers of a spina bifida affected 
child, 234 pediatric controls and 292 control women. MTHFDl 1958G>A genotyping 
was performed by RFLP. Possible associations between the MTHFDl 1958G>A SNP 
and spina bifida risk, plasma homocysteine and plasma and red blood cell (RBC) 
folate concentrations were examined using a case-control design. A transmission 
disequilibrium test [TDT] was conducted for 78 complete mother-father-child triads. 
The MTHFDl 1958AA genotype was not associated with spina bifida risk in mothers 
and children (OR:0.75; 95%CI:(U0-1.41 and OR:1.01; 95%CI:(U8-2.12 respectively]. 
The TDT demonstrated no preferential transmission of the MTHFDl 1958A allele 
from parent to spina bifida affected child (χ2=0.37, p=0.54). The MTHFDl 1958GA 
genotype might decrease maternal spina bifida risk (OR:0.62; 95%CI:0.38-1.03) and 
was associated with elevated RBC folate concentrations in control women (16.5% in­
crease 95%CI: 2.2% to 33.0%). In our Dutch study population, the MTHFDl 1958G>A 
SNP is no major risk factor for spina bifida in mothers and children. 
54 
3 MTHFDl 1958G->A and spina bifida risk 
I n t r n H i i r t m n ^ ^ e t r i " f u n c t i o n a ^ methylenetetrahydrofolate dehydroge-
nase/methenyltetrahydrofolate cyclohydrolase/formyltet-
rahydrofolate synthetase (MTHFDl ] enzyme plays a central role in folate metabolism 
and catalyzes the conversion of tetrahydrofolate (THF) into 10-formyl, 5,10-methenyl 
and 5,10-methylene derivatives, which are important substrates for methionine syn-
thesis and de novo purine and pynmidme synthesis". 
In 1998 our group identified a 1958G>A (Arg653Gln) single nucleotide polymorphism 
(SNP) in the MTHFD1 gene that was present m both spina bifida patients and con-
trols with similar frequencies100. More recently, the MTHFDl 1958AA genotype has 
been demonstrated to be a maternal risk factor for having a neural tube defect 
(NTD) affected child in the Irish population (OR:1.52; 95%CI:1.16-1.99 and OR:1.49; 
95%CI:1.07-2.09 respectively)101102. In an Italian population the MTHFDl 1958GA/AA 
genotype increased NTD risk m both mothers and children (OR:1.67; 95%CI:1.02-
2.73 and OR:1.76; 95%CI:1.10-2.82 respectively)103. 
In this study, we examined a possible association between the MTHFDl 1958G>A 
SNP and spina bifida risk in our Dutch study population, using a case-control design. 
In addition, we conducted a transmission disequilibrium test (TDT) for 78 complete 
mother-father-child triads. Possible associations between the MTHFDl 1958G>A 
SNP and plasma folate, red blood cell (RBC) folate and plasma homocysteine con-
centrations were also examined. 
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Materials and methods 
Q t i i H v n n m il a t i n n ^ ^ e 5*υ(^ν population differs from the one we previously 
OlUay pOpUldllOn u s e d t o 5 t u d y t h e M T H F D 1 1 9 5 8 G > A SNP
100 Familial 
NTD patients (n=38] were excluded, the parents [là mothers and 66 fathers) of the 
70 sporadic spina bifida patients were included and the population was extended 
with spina bifida patients (n=39) and their parents (47 mothers and 37 fathers) re-
cruited from the Pediatric Neurology Department of the Radboud University Nijme-
gen Medical Center The study population now consisted of 109 spina bifida patients 
(61 girls and 48 boys, mean age 16 ü +/- 11 3), their mothers [n=121, mean age 42 89 
+/- 10 89) and their fathers (n=103, mean age 44 9 +/- 10 2) and has been described 
in detail before149 
The control group consisted of 500 volunteers recruited from a general practice in 
The Hague179 In this study we only included the 292 women out of this control group 
(mean age 50 55 +/- 13 47) The pediatric control group consisted of 234 children (119 
girls and 115 boys, mean age 8 4 +/- 6 4) The children of secondary school age were 
healthy volunteers and the younger children were, for ethical reasons, recruited m a 
hospital setting180 The local medical ethics committee approved the study 
For the present study DNA of 102 spina bifida patients, 116 mothers, 101 fathers, 265 
control women and 211 pediatric controls was available for genotypmg 
B : s N s . U ^ m : . . .1 ^ η ι - ^ > . ^ ν ; » ^ ι - ; ^ η < ~ Plasma total homocysteine concen-lochemical determinations . . n .,3C „ ^ ' H in rn™ ni3c 
tration was measured in bUIA plas­
ma by HPLC and fluorescence detection as previously described1 8 1 
Plasma folate and red blood cell (RBC) folate levels were determined using the 
Dualcount Solid Phase Boil Radio assay (Diagnostic Product Corporation, Los An­
geles, CA) 
PCR amplification and genotype 
H p t p r m i n a t i n n MTHFDl 1958G>A genotypmg was performed essentially 
as previously described by our group1 0 0 Primer annealing 
took place at 590C and the PCR product of 330 bp was cut by the restriction enzyme 
Mspl, which cuts the G allele m fragments of 8 bp, 56 bp, 70 bp and 196 bp 
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Table 6 
The MTHFDl 1958G>A genotype distribution and 
unadjusted ORs in mothers of a spina bifida affected 
child and female controls 
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50 l a 21 
22 119 51 
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Statistical analysis 
70 127 2) 
137 153 3) 
50 119 5] 
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Ο 62 10 38-1 03] 
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Statistical analysis 
Case-control study Odds ratios (ORs) and their 95% 
confidence intervals were calculated by means of 
logistic regression analysis The effect of the MTHFD1 1958G>A SNP on plasma ho­
mocysteine and plasma and RBC folate concentration was studied using linear re­
gression analysis Plasma homocysteine and plasma and RBC folate concentrations 
were logarithmically transformed prior to linear regression analysis 
Deviation form Hardy-Wemberg equilibrium was calculated to assess the accuracy 
of the genotypmg assay 
The power of the case-control study was calculated, using the Genetic Power Cal­
culator185 All tests were performed using SPSS software package version 12 0 1 
Statistical significance was accepted at a two-tailed p<0 05 or a 95% CI of an odds 
ratio that did not include 1 0 
Transmission disequilibrium test The relation between the MTHFD1 1958G>A geno­
type of the spina bifida patients and spina bifida risk was assessed by evaluating the 
transmission of alleles from heterozygous parents to their affected offspring using 
the TDT, a family based association test187 The power of the TDT was calculated us­
ing the Genetic Power Calculator185 
Results 
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Γ n t r n l e t H The MTHFDl 1958G>A SNP could be determined in 
LaSe-COntrOl SlUay 1 1 3 m o t h e r s o f a s p j n a b i f | d a affected child and 257 
control women. Genotype distribution did not differ from that expected under Hardy-
Weinberg equilibrium 1ρ=0.2Λ). The study had a power of 58% to detect a twofold 
increase in risk of having a spina bifida affected child. The MTHFDl 1958AA genotype 
was not associated with spina bifida risk in mothers (table 6). The MTHFD1 1959GA 
genotype tended to decrease the risk of having a spina bifida affected child (table 6) 
To increase power, the MTHFDl 1958GAand MTHFDl 1958AA genotypes were com­
bined, which resulted in a non-significant 34% decreased risk of having a spina bifida 
affected child relative to the MTHFDl 1958GG genotype (OR:0.66; 95%CI:(U1-1.05]. 
Table 7 
The MTHFDl 1958G>A genotype distr ibut ion and 
unadjusted ORs in spina bifida patients and 
pediatric controls 
MTHFDl 1958G>A SB patients |n=103) Pediatric controls |n=203) OR |95%CI) 
GG 31 (30.1) 71 [35.0] 1a 





34(16.7) AA 101(0 48-2.12) 
Number of persons and percentage (%) are depicted 
3 Reference group 
In 103 spina bifida patients and 203 pediatric controls, MTHFDl 1958G>A SNP ge-
notyping was successful. Genotype distribution m the pediatric control group did 
not deviate from that expected under Hardy-Weinberg equilibrium (p=0.99) and the 
power to detect a twofold increase in spina bifida risk was 52%. In children, the 
MTHFDl 1958GAand the MTHFDl 1958AA genotypes were not associated with spina 
bifida risk (table 7). Combining the MTHFDl 1958GA and MTHFDl 1958AA genotypes 
resulted in a non-significant 25% increase in spina bifida risk (OR:1.25; 95%CI:0.75-
2.08). 
τ · · ι · · ι · ι_ · i j . The TDT had a power of 35% 
Transmission disequilibrium test tn . . t a tlAin^IH inrroaco 
~ to detect a twofold increase 
in spina bifida risk. In this study there were 78 complete mother-father-child triads 
and there were 67 informative transmissions from heterozygous parent to child. In 
31 out of the 67 transmissions the MTHFDl 1958A allele was given to the child, which 
resulted in a non-significant χ2Τϋ of 0.37 (p=0.54). 
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TheMTHFDl1958G>ASNP 
anri mPtahnlitP«; T h e M T H F D 1 1958G>A SMP was not associated with 
plasma folate or plasma homocysteine concentration 
in mothers (data not shown). The MTHFDl 1958GA genotype, but not the MTHFDl 
1958AA genotype, increased RBC folate concentration with 16.5% in control women 
(95%CI:2.2%to33.0%). 
In children, the MTHFDl 1958G>A SNP was not associated with plasma homocyste-
ine concentration. The MTHFDl 1958GA genotype, but not the MTHFDl 1958AA gen-
otype, significantly increased plasma folate concentration in both pediatric controls 
and spina bifida patients [18.9% increase 95%CI: 1.1% to 39.8% and 38.0% increase 
95%CI: 12.2% to 69.7% respectively). There was no data on RBC folate concentration 
available for children. 
Discussion 
Using both a case-control study and a TDT, we did not find an association between 
the MTHFDl 1958G>A SNP and spina bifida risk m both mothers and children. The 
MTHFDl 1958GA genotype might be associated with a decrease in the risk of having 
a spina bifida affected child, although this was not significant in our study population. 
Interestingly, the MTHFD1 1958GA genotype, but not the MTHFDl 1958AA genotype, 
was associated with elevated RBC folate concentrations in control women. 
Based on the effect of the heterozygous MTHFDl 1958GA genotype on spina bifida 
risk, a larger effect of the MTHFDl 1958AA genotype would be expected. The obser-
vation that the MTHFD1 1958GA genotype decreases spina bifida risk in mothers and 
the MTHFDl 1958AA genotype does not is likely a chance finding. However, another 
explanation could be the fact that the active MTHFDl enzyme is a homodimer188190. If 
one MTHFDl protein contains an arginine and the other a glutamme at position 653, 
this could possibly complicate homodimer formation and impair MTHFDl function 
and activity. In the folate cycle MTHFDl competes with thymidylate synthase [TYMS) 
and methylenetetrahydrofolate reductase (MTHFR) for 5,10-methyleneTHF. A less 
active MTHFD1 enzyme might result in more conversion of 5,10-methyleneTHF to 5-
methylTHF by MTHFR and subsequently more homocysteine remethylation and thus 
more methyl groups available for transmethylation reactions. The possible decrease 
in maternal spina bifida risk associated with the MTHFDl 1958GA genotype might be 
explained by this improvement of transmethylation reactions. The observation that 
the MTHFD 1958GA genotype is associated with elevated RBC folate concentrations 
supports this idea, since it has been suggested that red blood cells exclusively con-
tain 5-methylTHF70. 
Using a case-control design and log-linear models, the MTHFDl 1958AA genotype 
59 
3 MTHFD11958G->A and spina bifida risk 
was demonstrated to be a risk factor for NTDs in mothers but not in children in an 
Irish study population101. When conducting a TDT however, the MTHFD1 1958G allele 
was preferentially transmitted from parents to NTD affected child, which is not what 
you expect when the MTHFD1 1958AA genotype is associated with NTD risk in the 
mother. Besides this contradictory finding, the MTHFD1 1958G>A genotype distri-
bution in one of the control groups differed from that expected under Hardy-Wem-
berg equilibrium'01. In a later study, the association between the MTHFD1 1958AA 
genotype and maternal NTD risk was observed in another Irish study population, 
which strengthens their conclusion that the MTHFD1 1958AA genotype is a maternal 
NTD risk factor in the Irish population102. However, in this second study of the same 
group the MTHFD1 1958G>A genotype distribution m the control group differed again 
from that expected under Hardy-Weinberg equilibrium102. In an Italian population the 
MTHFD1 1958GA/AA genotype increased NTD risk in both mothers and children103. 
Our current results are in line with our previously performed study in which the 
MTHFD1 1958G>A SNP was not associated with NTD risk in children100. Our results 
are however not m line with the reported data on the MTHFD1 1958G>ASNPand NTD 
risk in the Irish and Italian population. A possible explanation could be the fact that 
the studies have been performed in study populations with a different geographic 
background and the MTHFD1 1958G>A SNP might only be a risk factor for NTDs in 
specific populations, as is the MTHFR 677C>T SNP115. 
According to our findings, the MTHFD1 1958G>ASNP is no major risk factor for spina 
bifida in the Dutch population. The MTHFD1 1958GA genotype might even decrease 
the risk of having a spina bifida affected child, possibly by improving transmethyl-
ation reactions. However, results should be interpreted with caution because of our 
relatively small study population and more studies on the association between the 
MTHFD1 1958G>A SNP and spina bifida risk are warranted. 
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The methionine synthase 
reductase 66A>G poly-
morphism is a maternal 
risk factor for spina bifida 
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Λ k i e + r - r a f t ^ e m e t ' 1 i o n i n e synthase reductase IMTRR) enzyme restores me-
thionine synthase (MTR) enzyme activity and therefore plays an 
essential role m homocysteine remethylation. In some studies, the 66A>G polymor­
phism in the MTRR gene has been associated with increased neural tube defect (NTD) 
risk. Using a case-control design, we studied the association between the MTRR 
66A>G polymorphism and spina bifida risk in 121 mothers, 109 spina bifida patients, 
292 control women and 234 pediatric controls. Possible interactions between the 
MTRR 66A>G variant and the MTR 2756A>G polymorphism, the MTHFR 677C>T vari­
ant, plasma vitamin B12 and plasma methylmalonic acid (MMA) levels were exam­
ined in the 121 mothers and 292 control women. Meta-analyses were conducted to 
set the results of the case-control study in the context of eligible literature on the 
relation between the MTRR 66A>G variant and NTD risk. Finally, a Transmission Dis­
equilibrium Test (TDT) was performed for 82 complete mother-father-child triads to 
test for preferential transmission of the MTRR risk allele. In our case-control study, 
the MTRR 66A>G polymorphism had no influence on spina bifida risk in children (OR: 
0.6; 95%CI: 0.4-1.1). The MTRR 66GG genotype increased maternal spina bifida risk 
2.1 -fold (OR: 2.1 ; 95%CI: 1.3-3.3). This risk became more pronounced m combination 
with the MTHFR 677TT genotype (OR: 4.0; 95%CI: 1.3-12.5). Moreover, we demon­
strate a possible interaction between the MTRR 66GG genotype and high plasma 
MMA levels (OR: 5.5; 95%CI: 2.2-13.5). The meta-analyses demonstrated that the 
maternal MTRR 66GG genotype was associated with an overall 55% (95%CI: 1.04-
2.30) increase in NTD risk and that the MTRR 66GG genotype did not increase NTD 
risk in children (OR: 0.96; 95%CI: 0.46-2.01). These data show thai the MTRR 66GG 
genotype is a maternal risk factor for spina bifida especially when intracellular vita­
min B12 status is low. 
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I n f r n r l i i r * t i n n neural tube defects (NTDs] are the second most common 
congenital malformations after congenital heart defects 
and can result m severe disability or even death. Despite their prevalent occurrence, 
little is known about the etiology of these birth defects. 
Since the observation that periconceptional folic acid supplementation reduces the 
occurrence and recurrence risk of NTDs by BO-yO0//0'1752, much research on NTDs 
has focused on folate metabolism. 5-Methyltetrahydrofolate (5-methylTHF] is 
the mam circulating form of folate in the blood and can donate its methyl group 
to homocysteine, thereby linking the folate cycle to the homocysteine metabolism. 
The methyl group of 5-methylTHF is transferred to homocysteine via the cofactor 
cob(l)alamin by the methionine synthase (MTR) enzyme. Cob(l)alamin is readily oxi-
dized to cobllllalamin, which inactivates the cobalamin-MTR-enzyme complex. Me-
thionine synthase reductase (MTRR) restores MTR activity by reductive methylation 
of cobllllalamin, using S-adenosylmethionine as methyl donor631". 
Wilson et al. described a common variant within the flavin mononucleotide (FMN) 
binding domain of the MTRR gene, the 66A>G polymorphism, which leads to an 
amino acid change of isoleucme to methionine (I22M). They reported an association 
between this polymorphism and increased NTD risk, exclusively when vitamin B12 
levels were low1^. Later, Zhu et al. described an increase in NTD risk for both mo-
thers and their offspring when having the MTRR 66AG/GG genotype alone128. An effect 
of the MTRR 66A>G polymorphism on plasma homocysteine levels was described by 
Gaughan et al.146 U7 however, data are conflicting with other reports140 i" U8. 
To test whether the MTRR 66A>G polymorphism is a risk factor for spina bifida we 
conducted a case-control study for both mothers and children. Possible interactions 
between the MTRR 66A>G polymorphism and low vitamin B12 status reflected by 
plasma methylmalonic acid (MMA) levels, the MTR 2756A>G and the MTHFR 677C>T 
polymorphism were only studied in the mothers of a spina bifida affected child and 
the control women. To determine whether the association between the MTRR 66A>G 
variant and spina bifida risk is the result of a genotype effect in the child, a Trans-
mission Disequilibrium Test (TDT) was performed. A meta-analysis of eight relevant 
case-control studies (including our study) on the association between the MTRR 
66A>G variant and maternal NTD risk and a meta-analysis of seven eligible case-
control studies (including our study) on the relation between the MTRR 66A>G poly-
morphism and NTD risk in children were conducted. 
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Materials and Methods 
Qtiirlw n n n n l a t m n ^ ' i e stuc'y population was recruited in collaboration 
y r r w j th the BOSK and was extended by a group from the 
Pediatric Neurology Department of the University Medical Center Nijmegen. The 
BOSK is a Dutch society for patients with central nervous system defects and their 
parents and is a national organization. Spina bifida patients recruited from the Uni-
versity Medical Center Nijmegen represent a general spina bifida population from 
the region. The study group included 109 spina bifida patients (61 girls and AB boys, 
mean age 16.à +/- 11.3], their mothers (n=121, mean age 42.89 +/- 10.89] and their 
fathers (n=103, mean age ΛΛ.9 +/- l O ^ ) " 3 . 
The control group consisted of volunteers recruited from a general practice in The 
Hague. A total of 2812 individuals aged 20-90 years, were invited to participate m 
a health survey of risk factors for cardiovascular disease. Five hundred thirty-two 
people agreed to participate and in this study, we only included the 292 women out 
of this control group [mean age 50.55 +/- 13.47). The individuals are unrelated and 
have no history of spina bifida and did not have a spina bifida affected child1 7 9. The 
constitution of the pediatric control group has been described previously'80. Briefly, 
the control group consisted of 234 children (119 girls and 115 boys, mean age 8.4 +/-
6.4). The children of secondary school age were healthy volunteers and the younger 
children were, for ethical reasons, recruited m a hospital setting. Exclusion criteria 
were overt liver and renal dysfunction, hormonal therapy, neoplastic disease and 
closure defects such as cleft lip and spina bifida. Informed consent (written or oral) 
was obtained from all participants. The local medical ethics committee approved the 
study. 
Laboratory determinations P[a5™ ma[ homocystH
eine "£ 
/ centration was measured m EDTA 
plasma by HPLC and fluorescence detection, as previously described by Te Poele-
Pothoff et al.'β'. 
Vitamin B12 levels in plasma were determined using the Dualcount Solid Phase Boil 
Radio assay (Diagnostic Product Corporation, Los Angeles, CA). 
Plasma MMA levels were measured, using HPLC combined with electrospray ioniza­
tion tandem mass spectrometry (LC-ESI-MS/MS). The LC-ESI-MS/MS system con­
sists of a Quattro LC (Waters Corporate, Milford, MA) connected to an HP1100 HPLC 
(Agilent Technologies, Palo Alto, CA) and a 232 XL autosampler (Gilson, Middleton, 
Wl). One hundred μι of plasma together with 100 μΐ of 0.8 _M stable isotope-labeled-
methyl-d3-malonic acid (MMA-d3) (Cambridge Isotope Laboratories, Andover, MA) 
as an internal standard, was deprotemized using ultra filtration. Subsequently, an 
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acidified aliquot of the ultra filtrate was injected onto a Waters Symmetry column 
(2.1 mmXI00mm, 3.5 μΜ). The mobile phase consisted of 15% methanol / 0.3% for­
mic acid and is eluted at 200 μΐ/min. Thereafter, the sample was analyzed by MS/MS 
monitoring the carbonyl loss of MMA and MMA-d3; recording the transition of m/z 
117 to m/z 73 and m/z 120 to 76 m/z, respectively. 
The MTR 2756A>G and MTHFR 677C>T polymorphisms had been genotyped, us­
ing restriction fragment length polymorphism (RFLP) analysis as previously de­
scribed7 3 1 2 6. 
• ι . • • . The MTRR 66A>G polymorphism does not 
HeteroduDlex aenerator , , , n,-, η ϊί * *• * ^ 
ι H...WI wuufji^sv ^v.! ι^ι u i v i Leacj t 0 a RpLp. therefore we first used 
pnmer-mtroduced restriction analysis (PIRA-PCR) for MTRR 66A>G genotypmg, as 
previously described by Wilson et al.1 4 1. However, this method appeared to be unreli­
able, resulting m a genotype distribution in the control group that was not m Hardy-
Weinberg equilibrium. Therefore a heteroduplexmg method, as described by Barbaux 
et al.1'2, was used to analyze the MTRR 66A>G polymorphism m our study population. 
A heteroduplex generator (HG) is a synthetic DNA molecule that is identical to the 
sequence of a short genomic fragment that includes the polymorphism of interest, 
except for a microdeletion close to the polymorphic site. The HG for determination of 
the MTRR 66A>G mutation was created by PCR-mediated site-directed mutagenesis 
(using the A allele as a template) and is characterized by a 3 bp microdeletion located 
3 bp downstream of the polymorphic site. The HG was cloned into the pGEM-T Easy 
(Promega, Fitchburg, Wl) and positive clones were identified by sequence analysis. 
PCR amplification and genotype 
r l o t o r m i n a t i r m ^ ^ amplifications were carried out m a volume of 50 μΐ, 
aeierminailOn c o n t a i n j n g 200 nM of the forward primer MTRR1 (S'-GAG-
GAGGTTTCTGTTACTATATGC-3·), 200 nM of the reverse primer MTRR4 (S'-GTGAA-
GATCTGCAGAAAATCCATGTA-3·) (Biolegio BV, Maiden, The Netherlands), 200 μΜ 
dNTPs, 2.0 mM MgCl2, 20 mM Tris-HCl pH 8.2, 50 mM KCl and 0.5 U Taq polymerase 
(all from Invitrogen, Breda, The Netherlands). 
Genomic DNA and the MTRR 66A>G HG were amplified separately. PCR conditions 
were: initial denaturation at 950C for 5 minutes, followed by 35 cycles of: 1 minute 
at 950C, 1 minute at 550C and 30 s at 720C and a final extension cycle of 7 minutes 
at 720C. Amplification products of genomic DNA fragments and HG were mixed 1:1 
and denatured for 5 minutes at 950C to facilitate subsequent heteroduplex forma­
tion. Products were mixed with loading buffer (2.5 g/L bromphenol blue, 0.36 v/v 
glycerol 87% and 10mM Tris, pH 9.2) and electrophoresed on a 17,5% Polyacrylamide 
gel (19:1) for 2-3 hours at 150 V in 1x Tris-borate-EDTA buffer. Gels were stained 
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with ethidium bromide (1 mg/L) followed by direct genotyping because the differently 
sized protruding loops of the heteroduplexes resulted in a unique migration pattern 
for each MTRR 66A>G genotype. 
Ç t a t i ^ t i r a l a n a l y t i c Case-control study Odds ratios [ORsI and their 95% 
' confidence intervals (CI) were calculated by means 
of logistic regression analysis. ORs were not adjusted, except those concerning me-
tabolites, which were adjusted for age. Plasma homocysteine, vitamin B12 and MMA 
concentrations were positively skewed. Therefore, these variables were logarithmi-
cally transformed before all statistical analyses. 
The association between the MTRR 66A>G variant and plasma homocysteine con-
centration was studied by means of linear regression analysis. Adjustments were 
made for age and sex. 
To define elevated plasma MMA levels, the 80th percentile of the control distribution 
was used [0.2Λ pmol/L). A decreased level of plasma vitamin B12 was defined as a 
concentration below the 20,h percentile of the control distribution (158 pmol/L). 
The power of the case-control study was calculated, using the Genetic Power Cal­
culator1 9 5. 
All tests were performed using SPSS software package version 12.0.1. Statistical 
significance was accepted at a two-tailed p<0.05 or a 95% CI of an OR that did not 
include 1.0. 
Table 8 
MTRR 66A>G genotype distr ibution and unadjusted 
ORs in mothers of a spina bifida affected child and 
control women 
MTRR66A>G Mothers |n=116) Female controls |n=264| OR (95% CI) 
AA 18(15.5) 53 120.1) 1 a 
AG 45(38.8) 135(51.1) 1.0(0.5-5.8) 
GG 53(45.7) 76(28.8) 2.1(1.1-3.9) 
The number of subjects and percentage in parentheses for each MTRR genotype are indicated 
' Reference group 
Meta-analysis By searching the electronic literature (MEDLINE) for papers on the 
MTRR 66A>G variant and NTD risk using the terms MTRR, methionine synthase re­
ductase, NTD, neural tube defects, SB and spina bifida and by hand-searching refer­
ence lists of original reports, we identified seven eligible publications on the MTRR 
66A>G variant and maternal NTD risk and seven studies on the MTRR 66A>G vari­
ant and NTD risk in children. One study on the MTRR 66A>G variant and NTD risk 
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in children only presented allele frequencies and was therefore excluded from the 
meta-analysis129. 
From each study information was extracted on the genotype frequencies among 
cases and controls and ORs (and 95% CI) were calculated based on these genotype 
frequencies. The risk of NTD was calculated for the MTRR 66GG genotype relative to 
the MTRR 66AA genotype. Because of the relative limited number of reports on the 
association between the MTRR 66A>G polymorphism and NTD risk, studies were not 
stratified based on their study design or continent of origin. Deviations from Hardy-
Weinberg equilibrium may cause bias when estimating the magnitude of the asso­
ciation between the MTRR 66A>G variant and NTD risk193, therefore meta-analyses 
were also performed after exclusion of the studies that were not in Hardy-Weinberg 
equilibrium. 
Transmission Disequilibrium Test The relationship between the genotype of the spi­
na bifida patients and spina bifida risk was assessed by evaluating the transmission 
of alleles from heterozygous parents to their affected offspring using the Transmis­
sion Disequilibrium Test (TDT), a family based association test187. The power of the 
TDT was calculated using the Genetic Power Calculator185. 
Table 9 
MTRR 66A>G genotype distr ibution and unad­
justed ORs in spina bifida patients and pediatric 
controls 













The number of subjects and percentage in parentheses for each MTRR genotype are indicated 
Λ Reference group 
Results 
Case-control study The MTRR 66A>G genotype could be determined m 
116 out of 121 mothers and in 264 out of 292 control 
women. The case-control study had a power of 65% to detect a twofold increase m 
maternal spina bifida risk. The genotype distribution was in Hardy-Weinberg equi­
librium (p=0 62). The distribution of MTRR 66A>G genotypes in mothers and controls 
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and ORs for maternal spina bifida risk are summarized in table 8. The observed 
MTRR 66G allele frequency was 0.54 in the controls and 0.65 m mothers with spina 
bifida offspring. The MTRR 66GG genotype increased the risk for mothers to have 
a child with a spina bifida twofold, compared to the MTRR 66AA genotype (OR: 2.1; 
95%CI: 1.1-3.9) or the MTRR 66AG genotype (OR: 2.1; 95%CI: 1.3-3.4). Because the 
risk of having a spina bifida child associated with the MTRR 66GG genotype was 
equally relative to both other MTRR genotypes, MTRR 66AA and MTRR 66AG indi­
viduals were combined for all further analyses. The MTRR 66A>G polymorphism did 
not significantly influence maternal plasma total homocysteine (tHcy) levels (data 
not shown). 
In 99 out of 109 spina bifida patients and 213 out of 234 pediatric controls, the MTRR 
66A>G genotype could be determined. The power to detect a twofold increase in 
spina bifida risk in children was 58%. The MTRR 66A>G genotype distribution was 
in Hardy-Weinberg equilibrium (p=0.76). The distribution of MTRR 66A>G genotypes 
in spina bifida patients and pediatric controls and odds ratios for spina bifida risk 
are summarized in table 9. The observed MTRR 66G allele frequency was 0.61 in 
the pediatric controls and 0.54 in spina bifida patients. In children, the MTRR 66GG 
genotype did not increase spina bifida risk relative to the MTRR 66AA/AG genotype 
(OR: 0.6; 95%CI: 0.4-1.1). Also, in children, the MTRR 66A>G polymorphism did not 
affect plasma tHcy levels (data not shown). 
Figure 10 
Meta-analysis for the 
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Data from eight case-control studies (including our study) on the MTRR 66A>G vari­
ant and maternal NTD risk was obtained. Figure 10 demonstrates the ORs of mater­
nal NTD risk associated with the MTRR 66GG genotype relative to the MTRR 66AA 
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M o t a a n a l v c i c 9 e n o t y P e · The MTRR 66GG genotype was associated with 
·' an overall increase in the risk of having a child with a NTD 
of 55% (OR: 1.55; 95%CI: 1.04-2.30). After exclusion of studies with a MTRR 66A>G 
genotype distribution that was not in Hardy-Weinberg equilibrium1 3 0, the MTRR 66GG 
genotype was sti l l associated with an increased risk of having a NTD affected child 
(OR: 1.54; 95%CI: 1.02-2.34) (data not shown). There might be some heterogeneity 
between the results of the studies (χ2= 13.779; p=0.055). 
Data from seven case-control studies (including our study) on the MTRR 66A>G vari­
ant and NTD risk in children was obtained. Figure 11 demonstrates that the MTRR 
66GG genotype is not associated with NTD risk in children (OR: 0.96; 95%CI: 0.46-
2.01 ). After exclusion of those studies with a MTRR 66A>G genotype distribution that 
was not in Hardy-Weinberg equilibrium9 7·1 3 0, the MTRR 66GG genotype was not as­
sociated with NTD risk in children (OR: 1.35; 95%CI: 0.80-2.29) (data not shown). 
There might be some heterogeneity between the results of the studies (χ2= 34.912; 
p=0.000). 
Figure 11 
Meta-analysis for the MTRR 66GG genotype relative to the 
MTRR 66AA genotype in chi ldren 
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~ preferential transmission of 
the MTRR risk allele from parents to child. There were 82 complete mother-father-
child triads and there were 80 informative heterozygous parents. The power of the 
TDT to detect a twofold increase in spina bifida risk was 39%. In 33 out of the 80 in­
formative transmissions (41.25%), the MTRR 66G allele was given to the child, which 
resulted in a non-significant χ2 of 2.45 (p=0.12). Although the power of the TDT is 
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low, these results suggest that there is no preferential transmission of the MTRR 
66G allele from parents to spina bifida affected child. 
Vitamin B12 and methylmalonic acid We examined the P°S 
* sible interaction be­
tween the MTRR 66A>G polymorphism and plasma vitamin B12 levels in mothers 
of a spina bifida affected child relative to the control group. Mothers with the MTRR 
66GG genotype combined with low plasma vitamin B12 levels had a nonsignificant 
1.7 fold increased risk of having spina bifida offspring, compared to mothers with 
the MTRR 66AA/AG genotype and normal plasma vitamin B12 levels (OR: 1.7; 95%CI: 
0.7-4.0) (data not shown). 
Because plasma MMA is a better indicator of the intracellular vitamin B12 status 
than total vitamin B12 levels in plasma, a possible interaction between the MTRR 
66A>G genotypes and plasma MMA levels was also determined. Information on both 
MTRR 66A>G genotype and plasma MMA concentration was present m 113 mothers 
and 261 control women. Table 10 demonstrates that mothers with the MTRR 66GG 
genotype m combination with high plasma MMA levels had an approximately 5.5-fold 
increased risk of having a spina bifida affected child [OR: 5.5; 95%CI: 2.2-13.5). 
Table 10 
Malernal spina bifida risk for the combina­
tion of the MTRR 66A>G polymorphism and 
ptasma MMA levels, adjusted for age 
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bThe 80th percentile of the control plasma MMA distribution was used to define elevated plas­
ma MMA levels 
Methionine synthase and methyl-
enetetrahydrofolate reductase ^TR 2756A>G g 6 ™ ^ 6 5 hau
d 
' been determined m I IA moth­
ers and 251 control women1 2 6 and its distribution was in Hardy-Weinberg equilibrium 
(p=0.91). Because individuals with the MTR 2756GG genotype were rare (1.6% in the 
control group), MTR 2756GG and 2756AG individuals were combined. Gene-gene in­
teraction between the MTRR 66A>G variant and the MTR 2756A>G polymorphism was 
examined. Information on both MTRR 66A>G genotype and MTR 2756A>G genotype 
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was present m 110 mothers and 249 control women. Mothers with both the MTRR 
66GG genotype and the MTR 2756GG/AG genotype had a threefold increased risk of 
having a spina bifida child, compared to mothers with the MTRR 66AA/AG genotype 
in combination with the MTR 2756AA genotype (OR: 3.0; 95%CI: 1.5-6.0] (table 11). 
A possible interaction between the MTRR 66A>G polymorphism and the MTHFR 
677C>T variant was also examined. The MTHFR 677C>T polymorphism had been de­
termined m 11Λ mothers and in 282 control women7 3. The MTHFR 677C>T genotype 
distribution was m Hardy-Weinberg equilibrium (p= 0.74). Information on both MTRR 
66A>G genotype and MTHFR 677C>T genotype was present in 111 mothers and 264 
control women. Table 12 demonstrates that mothers with the MTRR 66GG genotype 
m combination with the MTHFR 677TT genotype were four times more at risk of hav­
ing a child with spina bifida, compared to mothers with the MTRR 66AA/AG genotype 
and the MTHFR 677CC/CT genotype (OR: 4.0; 95%CI: 1.3-12.5). 
Discussion 
In this study, mothers with the MTRR 66GG genotype were two times more at risk of 
having a spina bifida affected child (OR: 2.1; 95%CI: 1.3-3.3). The MTRR 66GG geno­
type was not associated with spina bifida risk in children (OR: 0.6; 95%CI. 0.4-1.1). 
Zhu et al. reported the MTRR 66AG/GG genotype to be associated with an increase 
in NTD risk for both mothers and patients128. A Polish study also demonstrated an 
association between the MTRR 66GG genotype and NTD risk in mothers and chil­
dren; however, this risk was confined to lumbosacral NTDsU 2. In other studies, the 
MTRR 66GG genotype was not significantly associated with NTD risk in mothers and 
offspring 1 3 0 1 3 2 1 4 1 U 3 . In contrast to the previously discussed data, Relton et al. desig­
nated the A allele as risk factor for NTDs9697. Using a TDT, Doolin et al. also reported 
the A allele to be a risk factor for NTDs, only in mothers1 2 7. 
Table 11 
Maternal spina bifida risk for the combina­
tion of the MTRR 66A>G polymorphism and 
the MTR 2756A>G polymorphism 
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Data in literature on the association between the MTRR 66A>G variant and NTD risk 
and the designation of the MTRR 66A>G risk allele are contradictory and inconclu­
sive. To assess the relationship between the MTRR 66A>G polymorphism and NTD 
risk in both mothers and children, we conducted a meta-analysis in all eligible case-
control studies. A meta-analysis is an objective technique to review literature and is 
a valuable tool to place research findings in the context of published data. The meta­
analysis demonstrated an association between the MTRR 66A>G variant and mater­
nal NTD risk, increasing the risk by 55% when the MTRR 66GG genotype is present 
in mothers. The meta-analysis in children did not show an association between the 
MTRR 66GG genotype and NTD risk (OR: 0.96; 95%CI: 0.46-2.01). The results from 
the meta-analyses support the data obtained from our case-control studies that the 
MTRR 66GG genotype is a NTD risk factor that acts through the mother. 
Data from the TDT indicate that there is no preferential transmission of the MTRR 
66G allele from parents to their spina bifida affected child [p=0.12). Even though the 
TDT is underpowered, it supports the data found in the case-control study that there 
is no relation between the MTRR 66A>G variant and spina bifida risk in children. 
Because of the metabolic interrelation, we studied the possible interaction between 
the MTRR 66A>G polymorphism and vitamin B12 status in mothers and control wom­
en, using plasma vitamin B12 and plasma MMA levels. Plasma MMA levels were re­
ported to be a sensitive indicator of intracellular vitamin B12 status. Vitamin B12 up­
take into the cells is dependent on binding to and transport by transcobalamin (TC). 
In plasma, only 20% of the vitamin B12 present is bound to TC. indicating that total 
plasma vitamin B12 concentration is a poor estimate of the cellular vitamin B12 sta­
tus. Inside the cell vitamin B12 is required for homocysteine remethylation and for 
the conversion of L-methylmalonyl-CoA to succinyl-CoA by the vitamin B12 depen­
dent methylmalonyl-CoA mutase. Decreased intracellular vitamin B12 levels result 
in a decreased conversion of L-methylmalonyl-CoA and subsequently elevated MMA 
levels1 9 4 1'5. In this study, mothers with both the MTRR 66GG genotype and elevated 
plasma MMA levels were 5.5 times more at risk of having a spina bifida child (OR: 5.5; 
95%CI: 2.2-13.5), which suggests that the MTRR 66GG genotype is a maternal spina 
bifida risk factor, particularly when intracellular vitamin B12 status is low. This is m 
line with Wilson et al. who demonstrated an association between the MTRR 66GG 
genotype and decreased plasma vitamin B12 levels in elevating NTD risk"1. 
Table 12 
Maternal spina bifida risk for the combina­
tion of the MTRR 66A>G polymorphism and 
the MTHFR 677C>T polymorphism 
MTRR66A>G MTHFR 677C>T Mothers (%) Female controls (%) OR 195% CI) 
AAMG CC/CT 5 0 K 5 0I 172(65.2) 1 a 
AA/AG TT 9 ( 8 1 ) 16 [611 19(0.8-4.6) 
GG CC/CT 45(40 5) 70(26 5) 2 2(1.4-3.6) 
GG TT 7(6 3) 6(2 3] 4 0(1.3-12.5] 
' Reference group 
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The MTRR 66A>G polymorphism did not influence plasma homocysteine levels m 
our study population. In contrast, Gaughan et al. found a relative risk of 1.59 (95%CI 
1.10-2 25) for having homocysteine levels in the top half of the distribution for MTRR 
66GG homozygotes1"1". Other studies however, could not find such an effect of the 
MTRR 66A>G polymorphism on homocysteine concentration1'0 U1 U8. These data in-
dicate that the influence of the MTRR 66A>G polymorphism on spina bifida risk acts 
differently than via altering plasma homocysteine concentration. 
The I22M variant is located in the putative FMN binding domain of the MTRR enzyme 
that is suggested to interact with MTR. Substitution of an isoleucine by a methio-
nine m this part of the enzyme could thus disrupt the binding of MTRR to the MTR-
coblDalamm-complex. thereby decreasing the rate of homocysteine remethylation. 
Not much is known about the influence of the 66A>G mutation (I22M) on MTRR en-
zyme activity. One study by Olteanu et al. demonstrated that the required molar ratio 
of MTRR to MTR was fourfold higher for maximal activation for the M22 variant com-
pared to the 122 variant144. This suggests that the I22M variant m the MTRR enzyme 
disrupts the binding of MTRR and MTR. 
When MTRR function is impaired, it is likely that less methionine wil l be formed, 
leading to decreased AdoMet formation. Decreased formation of AdoMet wil l subse-
quently lead to reduced transfer of methyl groups by AdoMet, thereby disturbing the 
methylation, and thus expression and function, of genes and proteins, e.g. involved 
in neural tube closure. As early as 1990 Coelho and Klein suggested a role for pro-
tein methylation in proper neural tube closure30. An additional effect of an impaired 
MTRR enzyme is the reduced conversion of 5-methylTHF to tetrahydrofolate (THF), 
which may subsequently lead to a decreased availability of folate for purine and thy-
midine synthesis. During neurulation, cell proliferation is extremely fast and DNA 
requirement is subsequently high. Decreased availability of the DNA nucleotides 
could therefore lead to a disturbed neurulation, resulting in NTDs. 
Data from the case-control studies and meta-analyses in this study demonstrate 
that mothers with the MTRR 66GG genotype are more likely to have spina bifida af-
fected offspring. In combination with the MTHFR 677TT genotype, the MTRR 66GG 
genotype increased the risk of having spina bifida affected offspring even more. We 
observed a possible interaction for the MTRR 66GG genotype and high plasma MMA 
levels, demonstrating the importance of cellular availability of vitamin B12 for proper 
neural tube closure. These observations support the multifactorial etiology of neural 
tube closure defects and suggest an important role for vitamin B12 m the process of 
neurulation. 
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Λ h e f r O ^ t ^ e S9AG>T single nucleotide polymorphism (SNP) in the endothe-
M U o l l a U l ^ j a ^ î iQg (N0S3) gene, has recently been associated with embry­
onic spina bifida risk. In this study we examined the association between the N0S3 
894G>T SNP and spina bifida risk in a Dutch population. Using both a case-control 
design and a transmission disequilibrium test (TDT), a possible association between 
the N0S3 89Λ6>Τ SNP and spina bifida risk in both mothers and children was exam­
ined. Possible interactions between the N0S3 894G>T SNP and the MTHFR 677C>T 
SNP, elevated plasma homocysteine and decreased plasma folate concentrations 
were also studied. The N0S3 894TT genotype did not increase spina bifida risk m 
mothers or children (OR:1.50; 95%CI:0.71-3.19. 0R:1.78; 95%CI:0.75-4.25 respec­
tively). The TDT demonstrated no preferential transmission of the N0S3 894T allele 
(χ2=0.06, p=0.81). In combination with the MTHFR 677TT genotype or elevated plas­
ma homocysteine concentrations, the N0S3 894GT/TT genotype increased maternal 
spina bifida risk (OR:4.52; 95%CI:1.55-13.22 and OR:3.38; 95%CI:1.46-7.84 respec­
tively). In our study population, the N0S3 894GT/TT genotype might be a risk factor 
for having a spina bifida affected child in mothers that already have an impaired 
homocysteine metabolism. 
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I n t r n H i i r * t i n n Nitric oxide synthase (NOS) catalyzes the generation of ni-
Ι Π ΐ Γ O C J U C l l O n t r J c o x J d e i N o i ^ n important signaling molecule that medi­
ates many of its biological effects by activating the enzyme guanylyl cyclase hereby 
increasing cyclic GMP synthesis196. Besides its important role in cardiovascular con­
trol, NO has been suggested to play a role in development197. NO has been demon­
strated to be present in the neural tube of chick embryos at the time of neurulation1 9 8 
and regulates the balance between mitosis and programmed cell death199. Other 
studies show that NO can inhibit methionine synthase (MTR) enzyme activity, hereby 
interfering with homocysteine remethylation2 0 0 and proper neurulation2 0 1 2 0 2. 
The 894G>T single nucleotide polymorphism (SNP) in the endothelial derived nitric 
oxide synthase (N0S3) gene, identified by Hingorani et al.2 0 3, was shown to be associ­
ated with elevated plasma homocysteine levels in nonsmokers with low serum folate 
concentration2 0 4. More recently, it was demonstrated that the N0S3 894GT genotype 
is an embryonic risk factor for spina bifida (OR: 1.63; 95%CI:1.09-2.Λ2)205. 
In this study, we examined the relation between the N0S3 894G>T SNP and spina 
bifida risk in both mothers and children using a case-control design and a transmis­
sion disequilibrium test (TDT). An effect of the N0S3 894G>T SNP on plasma homo­
cysteine or plasma folate concentration was examined as well as possible interac­
tions between the N0S3 894G>T SNP and the MTHFR 677C>T SNP, elevated plasma 
homocysteine and decreased plasma folate concentrations. 
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Materials and methods 
Study population The study population has been described in detail be­
fore 1 ". Briefly, the study population was recruited in 
collaboration with the BOSK and was extended by a group from the Pediatric Neu­
rology Department of the Radboud University Nijmegen, Medical Center. The study 
group included 109 spina bifida patients (61 girls and 48 boys, mean age 16.k +/-
11.3), their mothers ln=121, mean age 42.9 +/- 10.9) and their fathers (n=103, mean 
age44.9+/- 10.2) 
The control group consisted of 500 volunteers recruited from a general practice m 
The Hague17'. In the present study we only included the 292 women out of this con­
trol group (mean age 50.6 +/- 13.5). The pediatric control group included 234 chil­
dren (119 girls and 115 boys, mean age 8.4 +/- 6.4)180. The children of secondary 
school age were healthy volunteers and the younger children were, for ethical rea­
sons, recruited m a hospital setting. The local medical ethics committee approved 
the study. 
For the present study DNA of 102 spina bifida patients, 116 mothers, 101 fathers, 265 
control women and 211 pediatric controls was available for genotypmg. 
Table 13 
The NOS3 894G>T genotype distr ibut ion and un­
adjusted ORs in mothers o( a spina bifida alfecled 





' Reference group 
Mothers (%) 
49 (42 61 
53(46 1) 
13(11.31 






1 33(0 83-2.11) 
1.50(0 71-3.19) 
n . ι · 1 _i j . ' j . · Plasma total homocysteine con-
Biochemical determinations c e n t r a t l 0 n w a s m e a s u r e d in EDTA 
plasma by HPLC and fluorescence detection, as previously described by Te Poele-
Pothoff et al.1 9 1. Plasma folate concentration was determined using the Dualcount 
Solid Phase Boil Radio assay (Diagnostic Product Corporation, Los Angeles, CA). 
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PCR amplification and genotype 
d e t e r m i n a t i o n N0S3 894G>Tgenotyp.ng was performed according to H.n-
goram et a l/ U J . Primer annealing took place at a tempera­
ture of 58°C. The PCR product of 206 bp was cut by the restriction enzyme Mbol, 
which cuts the Τ allele in fragments of 119 bp and 87 bp. 
S t a t i é t i r a i a n a l v ^ i ç Case-control study Odds ratios [ORs] and their 95% 
^ confidence intervals were calculated by means of 
logistic regression analysis. The effect of the NOS3 89Λ6>Τ SNP on plasma homo­
cysteine and plasma folate concentration was studied by means of linear regression 
analysis. Since the distributions of plasma homocysteine and plasma folate con­
centrations are positively skewed, these variables were logarithmically transformed 
prior to linear regression analysis. 
Deviation form Hardy-Wemberg equilibrium was calculated to assess the accuracy 
of the genotyping assay. 
The power of the case-control study was calculated, using the Genetic Power Cal­
culator185. All tests were performed using SPSS software package version 12.0.1. 
Statistical significance was accepted at a two-tailed p<0.05 or a 95% CI of an odds 
ratio that did not include 1.0. 
Table 14 
The NOS3 894G>T genotype distribution and un­
adjusted ORs in spina bifida patients and pediatric 
controls 
NOS3 894G>T SB patients (%l Pediatric controls (%) OR (95%CI) 
GG 39(41.1] 111(53.6] 1 a 
GT A6U8.4) 80(38.6] 1.64(0.98-2.74) 
TT 10(10.5] 16(7.7) 178(0.75-4 25) 
' Reference group 
Transmission disequiUbrium test The relation between the NOS3 894G>T geno­
type of the spina bifida patients and spina bifida risk was assessed by evaluating the 
transmission of alleles from heterozygous parents to their affected offspring using 
the TDT; a family based association test187. The power of the TDT was calculated us­
ing the Genetic Power Calculator185. 
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Results 
r^QP rnntrnl QtuHv T h e N 0 S 3 8 9 ^ G > T g e n o t y P e c o u l d b e determined m 
UdSti-LUIIU UI ölUUy 1 1 5 m o t h e r s o f a S p i n a b | f | d a affected child and in 
259 female controls. Genotype distribution did not differ from that expected under 
Hardy-Weinberg equilibrium (p=0.83) and the power to detect a twofold increase in 
maternal spina bifida risk was 59%. Table 13 demonstrates that the N0S3 894GT 
genotype as well as the N0S3 89ΛΤΤ genotype did not increase maternal spina bifida 
risk relative to the N0S3 894GG genotype. Since the effect of the N053 B9ÜGJ geno-
type and the N0S3 894TT genotype on spina bifida risk was the same relative to the 
N0S3 894GG genotype, the N0S3 894GT and TT genotypes were combined to increase 
power, which resulted m a non significant 36% increased risk of having a spina bifida 
affected child relative to the N0S3 894GG genotype (OR:1.36; 95%CI:0.87-2.11). The 
N0S3 894G>T SNP was not associated with plasma homocysteine or plasma folate 
concentrations in mothers and female controls (data not shown). 
In 95 spina bifida patients and 207 pediatric controls NOS3 894G>T genotypmg was 
performed successfully. The N053 894G>T genotype distribution did not differ from 
that expected under Hardy-Weinberg equilibrium (p=0.76] and the power of the study 
was 51%. The NOS3 89Λ6Τ genotype increased spina bifida risk in children whereas 
the NOS3 89ΛΤΤ genotype did not (table U). Combining the NOS3 894GT and 894TT 
genotypes resulted in a 66% increase in spina bifida risk relative to the N053 894GG 
genotype (OR:1.66; 95%CI:1.02-2.72). In the pediatric controls the NOS3 894GT and 
894TT genotypes were associated with increased plasma homocysteine concentra­
tions relative to the NOS3 894GG genotype (U.7% increase, 95%CU.2%-26.2% and 
23.5% increase, 95%CI:3.9%-46.8% respectively). There was no association between 
the NOS3 894G>T SNP and plasma folate concentration m children [data not shown). 
Table 15 
Maternal spina bifida risk lor the combi 
nation of the NOS3 B9iG>T SNP and the 
MTHFR6770TSNP 
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1 02(0 37-2 77] 
1.15(0 71-1.85] 
4 52(1 55-13 22) 
a Reference group 
-r •· ·ι·ι_ · j . j . In this study there were 75 
Transmission disequilibrium test c o m p l e t e
 y
m other-father-
child triads and the power to detect a twofold increase in spina bifida risk was 32%. 
In 36 out of 70 informative transmissions (51.A%}. the NOS3 89ΛΤ allele was trans­
mitted to the child, which resulted m a χ2 of 0.06 (p=0.81 ). 
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3 the MTHFR 677C>T genotype was present for 
110 mothers of a spina bifida affected child and 259 control women. Since the MTHFR 
677CT genotype did not increase spina bifida risk relative to the MTHFR 677CC 
genotype, we decided to combine the MTHFR 677CC and CT genotypes to increase 
power. In combination with the MTHFR 677TT genotype, the NOS3 894GT/TT geno­
type increased the risk of having spina bifida affected offspring A.5 times relative to 
the N053 894GG genotype combined with the MTHFR 677CC/CT genotype 10R:4.52; 
95%CI:1.55-13.22) (table 15). 
In children, there was no interaction between the NOS3 894GT/TT genotype and the 
MTHFR 677TT genotype (OR;1.23; 95%CI:0.31-4.91) (data not shown). 
Gene-metabolite interactions 
Since the MTHFR 677C>T SNP is 
a genetic determinant of plasma 
folate and plasma homocysteine concentrations, possible interactions between the 
NOS3 894G>T SNP and these metabolites were examined in mothers. In combination 
with decreased plasma folate concentrations (< 8.52 nmol/L), the NOS3 894GT/TT 
genotype did not increase maternal spina bifida risk, relative to the NOS3 894GG 
genotype in combination with normal plasma folate concentrations (s 8.52 nmol/L) 
[OR:1 H ; 95%CI:CU9-2.67) [data not shownl.The risk of having spina bifida affected 
offspring increased to 3Λ fold when having the NOS3 894GT/TT genotype in combi­
nation with elevated plasma homocysteine concentrations (s 12.56 pmol/L) (OR:3.38; 
95%CI:1.46-7.841 (Table 16). 
Table 16 
Maternal spina bifida risk for the combmalion 
of the NOS3 894G>T SNP and elevated plasma 
homocysteine concentration, adjusted for age 
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Discussion 
1" 
0 66(0 26-1 65] 
1 17(0 69-1 96] 
3 38 (1 46-7 84] 
* Reference group 
b the 80,h percentile of the control ptasma homocysteine distribution was used to define 
elevated plasma homocysteine concentrations 
In this study, the NOS3 894TT genotype did not significantly increase spina bifida risk 
and the TDT demonstrated no preferential transmission of the NOS3 89ΛΤ allele. 
However, m combination with the MTHFR 677TT genotype or elevated plasma ho-
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mocysteme concentrations, the N053 894GT/TT genotype increased maternal spina 
bifida risk 4.5 and 3.U fold respectively. 
Using a likelihood ratio test (LRT) for both proband and mother trios, Brown et al. 
demonstrated the N0S3 894GT genotype, but not the N0S3 89ΛΤΤ genotype, to be an 
embryonic risk factor for spina bifida (OR: 1.63; 95%CI:1.09-2.42)205. Data from our 
case-control study might be in line with this observation of Brown et al. however, 
based on the effect of the heterozygous NOS3 894GT genotype on spina bifida risk, a 
larger effect of the NOS3 894TT genotype on spina bifida risk would be expected. The 
observation that the NOS3 894GT genotype increases spina bifida risk and the NOS3 
894TT genotype does not, could be explained as a chance finding, but could also be 
the result of lack of power, as also suggested by Brown et al.205. 
Despite the small numbers on which the analyses are based, the possible interac­
tions between the NOS3 894GT/TT genotype and the MTHFR 677TT genotype or el­
evated plasma homocysteine concentrations are interesting and may suggest a role 
for NOS3 uncoupling or S-nitrosation. The NOS3 894G>T SNP (Glu298Asp) has been 
suggested to impair NOS3 protein function and/or activity resulting in decreased 
NO production206,207, although results are contradictory208. Elevated homocyste­
ine concentrations have been demonstrated to switch the NOS3 enzyme to an un­
coupled state directed to the synthesis of reactive oxygen species (ROS) rather than 
NO synthesis209. The combination of the NOS3 894GT/TT genotype and elevated 
plasma homocysteine concentrations, may lead to such a decrease in NO levels that 
neurulation is hampered. NO can also react with homocysteine to form S-mtroso-
thiols, hereby modulating homocysteine availability210. As previously suggested by 
our group211, decreased NO levels may result in decreased S-mtrosothiol forma­
tion, resulting in less capturing of homocysteine into s-mtrosohcy. The subsequent 
increase in plasma homocysteine concentrations might influence proper neural tube 
closure, especially when plasma homocysteine concentrations are already high. 
The results of our study suggest that the NOS3 894G>T SNP is a spina bifida risk fac­
tor in the mother and not m the child. Our results furthermore indicate a role for the 
homocysteine metabolism in the detrimental effects asserted by the N0S3 894G>T 
SNP. More studies on the association between the NOS3 894G>T SNP and spina bi­
fida in larger populations are warranted. 
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* ι _ | . _ _ _ | . Epigenetic processes have been suggested to play an important 
role in determining complex disease risk. DNA methylation is part 
of the epigenetic code and is the leading mechanism regulating gene expression. In 
the present study we tested the hypothesis that an impaired DNA methylation is one 
of the mechanisms underlying the complex etiology of neural tube defects (NTDs) 
and examined a possible association between global DNA methylation and spina bi­
fida risk in a Dutch study population consisting of spina bifida patients and pediatric 
controls. Global DNA methylation was measured in DNA extracted from whole blood 
samples of 59 spina bifida patients and 55 pediatric controls using a new, highly 
sensitive and specific liquid chromatography-electrospray iomzation-tandem mass 
spectrometry (LC-ESI-MS/MS) method that measures the ratio of 5-methylcytosine 
over total cytosine. The global DNA methylation ratio was 4.66% |95%CI:4.62% to 
4.69%) in the pediatric controls and 4.48% (95%0Ι:4.4Γ/ο to 4.55%) in the spina bifida 
patients. Spina bifida patients had a significantly 0.17% (95%CI 0.09% to 0.25%) lower 
global DNA methylation ratio than the pediatric controls and a global DNA methyla­
tion ratio in the lowest quartile of the control distribution (<4.55%) was associated 
with a 3.9 fold increased spina bifida risk |OR:3.90; 95%CI:1.34-11.37). Global DNA 
methylation ratio was not related with age, sex, plasma folate, plasma homocysteine 
or the MTHFR 677C>T SNP. In this study we demonstrate an association between a 
low global DNA methylation ratio and spina bifida risk, which supports the hypoth­
esis that an impaired methylation plays a role in NTD etiology. 
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I n t r o d u c t i o n 'n ' ts s'mP^lc'ty anc' effectiveness, the protective effect of 
periconceptional folic acid supplementation in relation to 
the occurrence and recurrence risk of neural tube defects (NTDs) is a major clinical 
breakthrough and success'04752. One of the mechanisms that has been hypothesized 
to underlie this beneficial effect of folic acid supplementation in relation to NTDs is 
an impaired methylation54. 
Inside the cell, the primary function of folate is to carry one-carbon groups that are 
used for purine and pyrimidine synthesis as well as for methylation reactions212. DNA 
methylation is part of the epigenetic code, which encompasses chemical modifica-
tions such as DNA methylation and histone modifications that play a major role in 
determining the functional output of the information stored in the genome213·214. It is 
becoming more and more evident that besides genetic variation and environmental 
factors, epigenetic mechanisms play an important role in determining complex dis-
ease risk215. 
DNA methylation patterns are reprogrammed during early embryogenesis and are 
relatively stable thereafter216. Since dietary methyl donors are required to form the 
universal methyl donor S-adenosylmethionine (AdoMet) and the embryo is complete-
ly dependent on the mother, maternal nutrition before and during early pregnancy 
might influence DNA methylation of the embryo217. Waterland and Jirtle demonstrat-
ed this hypothesis to be true for Agouti mice218. Dietary methyl group supplementa-
tion of pregnant Agouti mice affected the coat color of the offspring and this effect 
on phenotype was directly linked to changes in CpG methylation of an epigenetic 
metastable transposable element218. 
In order to test the hypothesis that an impaired DNA methylation is one of the mech-
anisms underlying NTDs, we determined global DNA methylation in 59 spina bifida 
patients and 55 pediatric controls using a new, highly sensitive and specific LC-ESI-
MS/MS method262. 
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Materials and methods 
Q t i i r l v n n n n l a t i n n ^ e s t u ^ y population has been described in detail be-
y r r fore U 9 . Briefly, the study population was recruited in 
collaboration with the BOSK [a national organization for patients with a central ner­
vous system defect and their parents] and was extended by a group from the Pedia­
tric Neurology Department of the Radboud University Nijmegen Medical Center. The 
study group included 109 spina bifida patients. 
The pediatric control group included 234 children1 8 0. The children of secondary 
school age were healthy volunteers and the younger children were, for ethical rea­
sons, recruited m a hospital setting. The local medical ethics committee approved 
the study. 
Global DNA methylation was determined in 59 spina bifida patients (25 boys and 34 
girls, mean age 11.9 +/- 3.7) and 55 pediatric controls (32 boys and 23 girls, mean 
age 10.8 +/- 4.0] of which enough whole blood was available to extract DNA from. 
Global DNA methylation The whole blood used for DNA extraction 
was stored at -40oC for around ten years. 
Approximately one month before measuring global DNA methylation, DNA was fresh­
ly extracted from 250 μΙ_ whole blood using the salt extraction method described by 
Miller et al.2 1 9 and was subsequently stored at -20oC until usage. 
A 50 μΙ_ aliquot of the DNA solution, containing approximately 1 pg of DNA was hy-
drolyzed using formic acid and subsequently the cytosme and 5-methylcytosine were 
separated by gradient-elution reversed phase chromatography with a mobile phase 
containing nanofluoropentanoic acid (NFPA) as ion-pairing reagent and quantified 
using stable isotope dilution LC-E5I-M5/MS. The method was recently described in 
detail2 6 2. 
Biochemical determinations 
a n d n e n o t v n i n n Plasma total homocysteine concentration was measured 
in EDTA plasma by HPLC and fluorescence detection as 
previously described181. Plasma folate levels were determined using the Dualcount 
Solid Phase Boil Radio assay [Diagnostic Product Corporation, Los Angeles, CA). 
MTHFR 677C>T genotypmg was performed previously, using restriction fragment 
length polymorphism analysis73. 
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Figure 12 
Global DNA methylation ratio for individual pediatric 
controls and spina bifida patients 
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DiailStlCai analysis s p i n a b i f i d a p a t i e n t s a n d pediatric controls was 
calculated with an independent samples t-test. Odds ratios (ORs) and their 95% con­
fidence intervals [CIs) were calculated using logistic regression analysis with global 
DNA methylation as the independent variable that was categorized. The lowest quar-
tile of the control global DNA methylation ratio distribution was used to define a low 
global DNA methylation |<4.55%]. 
Correlations between global DNA methylation and age, sex, plasma folate or plasma 
homocysteine concentrations were determined in the pediatric control group and 
the spina bifida patients. Since the distributions of plasma folate and plasma ho­
mocysteine concentration are positively skewed, these variables were logarithmi­
cally transformed before analyses. A possible effect of the MTHFR 677C>T SNP on 
the global DNA methylation ratio was examined using linear regression analysis. All 
tests were performed using SPSS software package version U.O. Statistical signifi­
cance was accepted at a two-tailed p<0.05 or a 95% CI of an odds ratio that did not 
include 1.0. 
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Results 
and spina bifida risk 
Global DNA methylation 
Global DNA methylation was successfully deter­
mined in all 55 pediatric controls and 59 spina 
bifida patients. There was no correlation between age and global DNA methylation 
ratio in the pediatric controls (r=-0.16, p=0.26) or the spina bifida patients (r=-0.04, 
p=0.79) and global DNA methylation did not correlate with sex either (r=-0.09, p=0.53 
and r=-0.17, p=0.19 for pediatric controls and spina bifida patients respectively). 
Since global DNA methylation did not correlate with age and sex and the mean age 
and the sex ratio did not differ between the spina bifida patients and pediatric con­
trols, no adjustments were made for these two variables. 
The mean global DNA methylation ratio was 4.66% (95%CI: 4.62% to 4.69%) in the 
pediatric controls and 4.48% (95%CI: 4.41% to 4.55%) m the spina bifida patients 
(figure 12). Using an independent samples t-test, the global DNA methylation ratio 
m spina bifida patients was 0.17% (95%CI: 0.09% to 0.25%) lower than that in the 
pediatric controls. 
Logistic regression analysis demonstrated that the risk of having spina bifida in­
creased 3.9 fold when global DNA methylation ratios were in the lowest quartile of 
the control distribution (OR:3.90;95%CI:1.34-11.37) (table 17). 
MTHFR 677OT, plasma folate 
and plasma homocysteine Data on both 9lobal DNA m e t h y l a t l o n 
Q M U ρ ι α ο ι ι ι α u u y a i c i and the MTHFR 677C>T SNP was avail­
able for 54 pediatric controls and 58 spina bifida patients. Using linear regression 
analysis, we could not demonstrate an association between the MTHFR 6 7 7 0 T 
SNP and global DNA methylation m both controls and spina bifida patients (data not 
shown). 
Data on global DNA methylation and plasma folate concentration was available for 
54 pediatric controls and 55 spina bifida patients. Data on global DNA methylation 
and plasma homocysteine concentration was present for 55 pediatric controls and 
58 spina bifida patients. There were no correlations between global DNA methylation 
and plasma folate or plasma homocysteine concentrations m the pediatric controls 
(r=0 11, p=0.43 and r=-0.04, p=0.80 respectively) or the spina bifida patients (r=0.10, 
p=0.47 and r=0.01, p=0.92 respectively). 
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Table 17 
Spina bifida risk m chi ldren for quart i les 
of the global DNA melhylat ion ratio 

















Numbers of subjects and percentages l%l are depicted 
' 4lh guardie s i, 775%. 3rd quarti le < 4 775% and ä A 665%. 2nd 
quartile <i, 605% and s 4 55%. 1st quarti le <4 55% 
•' Reference group 
Discussion 
In the present study we demonstrate that spina bifida patients have a 0.17% lower 
global DNA methylation compared to control children of comparable age. A global 
DNA methylation ratio in the lowest quartile of the control distribution was associated 
with a 3.9 fold increased spina bifida risk. Since global DNA methylation patterns 
are relatively stable throughout life214, we assume that the global DNA methylation 
ratio, that was measured well after the event of neural tube closure, reflects global 
DNA methylation at the time of neurulation. We hypothesize that decreased DNA 
methylation during neurulation changes gene expression, which wil l subsequently 
hamper the complex process of proper neural tube closure. Since the embryo is 
completely dependent on the mother and the embryo is likely to be vulnerable for an 
impaired methylation because DNA methylation patterns are reprogrammed during 
early embryogenesis214 and genes are turned on and off in high pace at the time of 
neural tube closure, periconceptional folic acid supplementation of the mother may 
prevent NTDs by increasing the availability of methyl groups for methylation reac-
tions m the embryo. 
Studies of our group and others have suggested a link between an impaired meth-
ylation and NTD risk. Inhibition of methylation resulted m a decreased S-adenosyl-
methiomne/S-adenosylhomocysteine (AdoMet/AdoHcy) ratio and cranial closure 
defects in both mouse and chick embryos3876. The AdoMet/AdoHcy ratio was shown 
to be decreased in mothers of a NTD affected child220. The MTHFR 677C>T single 
nucleotide polymorphism [SNP) has been associated with decreased availability of 
one-carbon moieties for methylation reactions69 and neural tube defect risk73. And 
mactivation of the DNA methyltransferase DNMT3B disrupts de novo DNA methyla-
tion and causes NTDs in mice7'. 
A study by Ingrosso et al. demonstrated that the global DNA hypomethylation pre-
sent in hyperhomocystememic patients with uremia decreased after treatment with 
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folic acid and that this decrease in global DNA hypomethylation was accompanied by 
a shift from biallellic to monoallellic expression of the imprinted HI9 gene221. Other 
studies in rat222 and humans223 confirmed the observation from Ingrosso et al.221 that 
supplementation with folic acid increases DNA methylation. Waterland and Jirtle 
demonstrated that dietary supplementation with methyl donors of pregnant Agouti 
mice affected coat color in their offspring by increasing methylation of the epigenetic 
metastable agouli locus that contains a transposable element2'8. This observation 
that folic acid supplementation can affect DNA methylation and phenotypic changes, 
even m the offspring of the supplemented subject, provides the proof of principle that 
penconceptional folic acid supplementation of the mother can improve methylation 
m the embryo. 
In the present study global DNA methylation ratios were measured using a new 
highly sensitive and specific LC-ESI-MS/MS technique262. This method is very ac-
curate (with inta- and mter-assay coefficients as low as 1.7% and 3.5% respectively] 
and therefore we were able to identify small but very significant differences in global 
DNA methylation ratio between spina bifida patients and pediatric controls. 
The meaning of the decreased global DNA methylation ratio observed m spina bifida 
patients cannot be addressed by this study. The decrease in global DNA methylation 
may reflect decreased methylation of transposable elements224 or other regulatory 
sequences in the genome, repetitive elements, genes or areas of the genome with 
unknown function. To get more insight into the relation between decreased DNA 
methylation and NTDs, more studies on global DNA methylation, but especially gene 
specific methylation, in large human study populations as wel l as animal models are 
required. 
This study is the first to demonstrate an association between a low global DNA 
methylation and spina bifida risk and supports the hypothesis that an impaired DNA 
methylation plays a role m the complex etiology of NTDs. 
Our study underlines the critical importance of epigenetic mechanisms during de-
velopment. The degree to which this regulatory mechanism is established during 
early development may not only affect NTD risk but might also influence health and 
disease later in life. 
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» u — i . r — —A An impaired DNA methylation has been suggested to underlie the 
complex etiology of neural tube defects (NTDs). Previously, we 
have demonstrated that inhibition of methylation by periodate oxidized adenosine 
(Adox) results in a widening of the anterior neuropore (ANP) in our in vitro chick 
embryo model. Since DNA methylation is the chief regulator of gene expression, we 
hypothesize that inhibition of methylation by Adox in our in vitro chick embryo model 
wi l l affect the expression of genes that may be involved in neurulation. In the pre­
sent study we therefore examined differential gene expression between Adox treated 
and control chick embryos, using the Affymetnx Genechip® Chicken Genome Array. 
Chick embryos of 4/5 somites were cultured in vitro with saline (control) or Adox 
and cranial parts were excised. Gene expression profiling was determined using the 
Affymetnx Genechip® Chicken Genome Array on RNA isolated from two pools of 
Adox treated cranial parts (n=12) and two pools of saline treated cranial parts [n=12). 
Microarray data were validated by QPCR analysis. In the Adox treated chick embryos 
45 probesets were up regulated (fold ? 2.0, ρ < 0.05) and 32 probesets were down 
regulated [fold « 0.5, ρ < 0.05). Of the 15 genes selected for QPCR analysis the up 
regulation of phosphoserine phosphatase (PSPH), unc-51-like kinase 1 (ULK1) and 
chemokme (C-X-C motif) ligand 12/stromal cell-derived factor 1 (CXCL12/SDF-1) 
was confirmed. Inhibition of methylation by Adox affects gene expression in our in 
vitro chick embryo model. Further research wi l l focus on the gene specific methyla­
tion patterns of PSPH, ULK1 and CXCL12/SDF-1 and the role of the products of these 
genes in neurulation. 
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I n t r n r l i i r t i n n '* ^ a s ' D e e n 5 υ 9 9 θ 5 ΐ θ ^ that folic acid asserts its well known 
Ι ΠΐΓΟα UCUOn b e n e f l c i a l e f f e c t i n r e i a tJon to neural tube defects (NTDs)"
5 2 
via improving an impaired methylation54. The observations that the 677C>T single 
nucleotide polymorphism (SNP) in the methylenetetrahydrofolate reductase (MTHFR) 
gene is associated with decreased availability of methyl groups for methylation6 9, 
results in a reduction of global DNA methylation7 1 7 2 and is a genetic risk factor for 
NTDs73, support this hypothesis and suggest a role for DNA methylation m NTD etiol­
ogy. Inactivation of the DNA methyltransferase DNMT3B disrupts de novo DNA meth­
ylation and results in multiple developmental defects including NTDs in mice, which 
further underlines the relevance of DNA methylation during early development74. 
The hypothesis that a hampered methylation may induce NTDs was recently tested 
by our goup38. Using an in vitro chick embryo model transmethylation was inhibit­
ed with both methionine-adenosyltransferase (MAT) and S-adenosylhomocysteine 
hydrolase (AHCY) inhibitors. In this model, inhibition of transmethylation resulted 
in a reduced methylation ratio (S-adenosylmethionine/S—adenosylhomocysteine 
(Ado Met/Ado Hey)] and a dose-dependent widening of the anterior neuropore (ANP), 
indicating that cranial neurulation is complicated by inhibition of transmethylation 
reactions38. 
Since DNA methylation patterns are reprogrammed during early embryogenesis2'6, 
making the embryo probably more vulnerable for changes in methylation, and DNA 
methylation is an epigenetic mechanism that is the chief regulator of gene expres­
sion213, we hypothesize that inhibition of methylation in our in vitro chick embryo 
model wi l l affect gene expression. By identifying genes whose expression is influ­
enced by methylation inhibition in our in vitro chick embryo model we anticipate to 
identify genes that are involved in neural tube closure. In this study we cultured chick 
embryos and treated them with saline (control) or the methylation inhibitor peri­
odate oxidized adenosine (Adox). Cranial parts of chick embryos were harvested and 
differences in gene expression levels between control and Adox treated chick em­
bryos were determined by performing microarray experiments using the Affymetnx 
Genechip® Chicken Genome Array. 
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Materials and methods 
In vitro chick embrvo model Whlte Le9horn chlcken e995 were 
m viu υ uiiiurv cium yu inuuci s t o r e d a t 1 2 o C u p o n a r r | v a L a t t h e 
laboratory. At the start of experiments, the eggs were incubated in a roller incuba­
tor (Polyhatch, Brinsea Products, Sandford, UK) for 36-40 hours at 390C and 55% 
humidity. The in vitro chick embryo culture model has been previously described37. 
In short, embryos were dissected out of the egg and placed on a culture bottom con­
sisting of 0.5% agar (Difco, Detroit, Ml) in a solution of saline (Locke's solution: 154 
mM NaCl, 6 mM KCl, 2 mM CaCl2 and 10 mM D-glucose) and egg white (1:1). Only 
embryos with 3, k or 5 somites at the start of the experiments were cultured on the 
agar substrate since previous studies demonstrated that during this small window 
ANP closure was most sensitive for inhibition of transmethylation3 8. After an adapta­
tion period of 30 minutes at 390C, 80 μΙ_ of a freshly prepared 50 μΜ Adox solution 
or 80 pL of saline solution, both at 39':'C, was administered to the chick embryo after 
which an incubation of 3 hours at 390C took place. Treatment of the chick embryos 
with the methylation inhibitor Adox at a concentration of 50 μ M fora period of 3 hours 
was chosen, since a 50 μΜ Adox solution was the most potent methylation inhibitor 
with the largest effect on ANP closure after 3 hours of incubation38. Immediately be­
fore administration of the solution and after the 3-hour incubation period, digital im­
ages were made with a stereo microscope [Leica MZFLIII). The width of the ANP was 
measured with the program ImageJ. After the 3-hour incubation period embryos 
were washed with saline of 390C, the vitelline membrane was removed and the chick 
embryo was dissected between the second and third somite rendering the cranial 
part of the embryo that consists for more than 50% of neural plate tissue. 
R N A P Y t r a r t i n n Chick embryos for microarray experiments were selected 
based on the change in ANP width after 3 hours of incu­
bation. The ANP of saline treated chick embryos had to close and the ANP of Adox 
treated chick embryos had to open. The digital images of the chick embryos selected 
for microarray analyses based on the change in their ANP width were subsequently 
evaluated manually as well. 
RNA for microarray experiments was extracted for a pool of six cranial parts using 
Tnzol (Invitrogen, The Netherlands) and the carrier linear Polyacrylamide225. The six 
cranial parts were homogenized m 0.8 mL of Tnzol using a pestle. RNA was extract­
ed according to the manufacturer's protocol and was dissolved m 20 pL of DEPC-
treated water. 
Before DNase treatment two RNA samples that contain RNA of 6 cranial parts each, 
were pooled to obtain RNA pools derived from 12 cranial parts. RNA was subse-
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quently treated with Λ units of DNase (Ambion) for 30 minutes at 370C and was then 
extracted using the RNeasy clean-up protocol (Qiagen) and eluted with 30 μΙ_ of 
DEPC-treated water. 
RNA quantity was analyzed using a nanodrop spectrophotometer ND-1000 (Nano-
drop Technologies). RNA quality was checked on an Agilent 2100 Bioanalyzer. 
Table 18 














































































Gene expression profiling M i c r o a rI? l
Y
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x p e r:Te n t s T w o ρ ο ο ί ! Λ ! Γ 
r r -» taming RNA from 12 cranial parts of Adox 
treated chick embryos each and two pools containing RNA from 12 cranial parts of 
saline treated chick embryos each were used for gene expression analysis. From 
each pool 4.5 μg of total RNA was used for gene expression profiling. 
Gene expression analysis was carried out using the Affymetrix Genechip® Chicken 
Genome Array, following the manufacturer's protocol2 2 6. The Affymetrix Genechip® 
Chicken Genome Array contains 38,835 probesets corresponding to over 28,000 avian 
genes. In brief, double stranded cDNA was synthesized from Λ.5 μg of total RNA for 
each pool. The cDNA was subsequently used for in vitro transcription, during which 
fluorescently labeled ribonucleotides were incorporated and a one-cycle amplifica­
tion step took place. The cRNA was then randomly fragmentized to cRNA parts of 35 
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to 200 bases and hybridized to the array. Each pool was hybridized to a single array. 
After hybridization the sample was stained, washed and scanned in an Affymetrix 
GeneArray Scanner. 
Microarray analysis Alterations in gene expression were considered relevant when 
the difference was at least twofold and only those probesets were selected for further 
analysis. Data were subsequently normalized using RMA (robust microarray analy-
sisl-median normalization GeneSpring 7.2 software (Agilent), using the Benjamini 
and Hochberg false discovery rate multiple testing correction (a=0.05), to identify 
differentially expressed genes227. 
We had duplicate array measurements, which made it possible to compare intra-
condition variance with between-condition variance, as implemented by the error 
model in GeneSpring 7.2. Scatter-plots between replicate arrays indicated no spe­
cific biases. The call ratios of all four arrays, as computed with the Affymetrix GCOS-
server, exceeded Λ8%. 
GO-enrichment and KEGG-enrichment pathway analyses were performed. However, 
due to the little amount of annotation for the chicken genome, the enrichment pro­
vided less interesting results. Instead, the strategy was pursued to analyze differen­
tially expressed transcripts of interest. 
Figure 13 
During the 3-hour incubation period the 
ANP of the saline treated chick embryo 
narrows (A) and the ANP of the Adox 
treated chick embryo widens (Bl 
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- . , . · . . . . · η o r t From each pool 150 ng of total RNA 
Real-time quantitative PCR was r e v e r s ^ r t r a n s c r i b e
a
d t0 C D N A by 
standard techniques, using random primers (Invitrogen, Breda, The Netherlands! in 
a final reaction volume of 20 μΙ_. 
QPCR experiments were carried out m a total volume of 50 μΙ_ containing: 2μΙ_ of 80 
times diluted cDNA, 1 μ ι ΙΟχ sybrgreen (Molecular Probes), 200 nM of forward and 
reverse primers (table 18) (Biolegio BV, Maiden, The Netherlands), 200 μΜ dNTPs 
(Invitrogen, Breda, The Netherlands), 1x AmpliTaq Gold amplification buffer, k mM 
MgCl2 and 1 unit AmpliTaq Gold DNA polymerase (Applied Biosystems, Nieuwerkerk 
a/d Ijssel, The Netherlands). Q-PCR conditions were: initial denaturation at 95°C 
for 10 minutes, followed by 35 cycles of: 30s at 95',C, 30s at 580C and 30s at 72°C. 
After amplification, a melting curve was acquired by heating for 3 minutes at 95°C, 
cooling to 25°C and heating again to 95'>C with temperature intervals of 1°C per 
20s. Samples and experiments were run in duplicate on the Icycler id real-time PCR 
detection system (Biorad, Veenendaal, The Netherlands) and fluorescence was mea­
sured during each annealing step. 
Expression levels of the genes of interests (GOI's) were normalized to the reference 
genes ß-actin (ACTB), porphobilinogen deaminase (PBGD) and eukaryotic transla-
tion elongation factor 1 alpha 1 (EEFIAI) by comparative quantification, using the 
AACT method'
83. For each sample, the ACT was calculated [CT G0I - CT r J . The mean 
relative expression was calculated as 2"AACT (AÄCT = ACT .. - ACT . ). The geNorm 
r Τ Τ, Adox Τ saline -? 
software was applied to combine both the results of ACTB, PBGD and EEFIAI to 
obtain a more accurate normalization1 8 4. All QPCR experiments were carried out in 
duplicate. 
Table 19 
Up regulated probesets m the Adox treat­
ed chick embryos, using the Affymetnx 
Genechip® Chicken Genome Array 
Gene Function Fold change p-value 
Genes with 
known function 













0,0245 ANKRD50 ankynn repeat domain 50 
TBC1D8 TBC1 domain family, member 8 
[with GRAM domain) 2,095 0,0272 
DDX6 DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 6 7,596 0,0272 
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eukaryotic translation initiation 
factor 2C, 3 
protein inhibitor of activated STAT, A 
solute carrier family 7 [catiomc ammo 
acid transporter, y+ system), member 5 
splicing factor, argmine/senne-rich 15 
solute carrier family 25, member 37 




mterleukm 6 signal transducer (gp130, 
oncostatm M receptor) 
unc-51-like kinase 1 [C elegans) 
ChaC, cation transport regulator 
homolog 1 (E coli) 
diencephalon/mesencephalon homeobox 1 
nuclear receptor subfamily 1, group D, 
member 2 
Cul l in2 
Ubiquitm specific peptidase A9 
chemokme (C-X-C motif) ligand 12 
[stromal cell-derived factor 1) 
enhancer of mRNA decapping 3 homolog 
[S cerevisiae) 
amylase, alpha 1A, salivary 
core 1 synthase, glycoprotem-N-
acetylgalactosamme 3-beta-galacto, 
syltransferase, 1 
BTB (ΡΟΖ) domain containing 5 
Cadherin 6, type 2, K-cadhenn (fetal kidney) 
hypothetical LOCA20121 
similar to Wnt inhibitory factor 1 
precursor (WIF-1) 
similar to DRIM protein 
Transcribed locus, weakly similar to 
XP_359A52 1 protein MG05325 A 























































































Transcribed locus, weakly similar to 
NP_9830A5.1 [Eremothecium gossypii] 
hypothetical L0C415828 
similar to putative transmembrane protein 
similar to KIAA1821 protein 
similar to MGC86290 protein 
similar to transcription factor CP2-like 3 




Similar to MAP kinase kinase 6b 
similar to cytokme-like nuclear factor n-pac; 
3-hydroxyisobutyrate dehydrogenase-like 
Hypothetical protein, clone 1g12 
Similar to cytokine-like nuclear factor n-pac; 
3-hydroxyisobutyrate dehydrogenase-like 
similar to WD repeat domain 32 
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Results 
In vitro chick embryo model 'h e ^ e c t l v e ^ s of Adox ;n inh'bl 
1 ting transmethylation reactions has 
been demonstrated m a previous study from our group m which we demonstrated 
that the administration of 80 μΙ_ of a 50 μΜ Adox solution resulted m a 3-fold increase 
m AdoMet concentrations, a 40-fold increase in AdoHcy concentrations and a subse­
quent 13-fold decrease in the AdoMet/AdoHcy ratio3 8 In 63% of the 4-somite stage 
chick embryos treated with Adox the ANP widened and m 6Λ% of the saline treated 
4-somite stage chick embryos the ANP closed [figure 13) 






00l5 and the 
two control pools 45 probesets were up regulated in the Adox treated pools com­
pared to the control pools (fold change s 2 0, ρ < 0 05) [Table 19) Thirty-two probe­
sets were down regulated m the Adox treated pools compared to the control pools 
(fold s 0 5, ρ < 0 05) (Table 20) Of the 45 up regulated probesets, there were 16 genes 
with a known function, whereas from the down regulated probesets there were only 
5 genes with a known function 
r» • %.· Α Ι . j.· n ^ p » Based on four criteria, a set of 15 
Real-time quantitative PCR genes was seLected for valldatlon by 
QPCR analysis (table 21) First of all, the probeset had to be located in the coding re­
gion of the gene it was annotated for If more than one probeset was present for one 
gene, all probesets annotated for that gene and located m the coding region of that 
gene had to be differentially expressed Secondly, the fold change in gene expres­
sion between Adox treated and control pools had to be equal to or higher than two 
Thirdly, the p-value corrected for multiple testing had to be below 0 05 Finally the 
spot intensity of the probeset on the array had to be higher than 100 
Since the control genes that were used on the Genechip system (ACTB, GAPDH and 
EEF1A1) did not differ m expression level between the Adox treated and control pools, 
these genes were also used as control genes m the QPCR analysis From the 15 se­
lected genes the up regulation of the genes phosphosenne phosphatase (PSPH), 
unc-51-like kinase 1 (ULK1) and chemokme (C-X-C motif) ligand 12/stromal cell-de­
rived factor 1 (CXCL12/SDF-1) could be confirmed by QPCR analysis (table 21) 
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Table 20 
Down regulated probesets in the Adox 
treated chick embryos, using the Affyme-
tnx Genechip® Chicken Genome Array 








































homeo box B3 
MAX dimenzation protein 4 
pleckstrin homology domain containing, 
family 0 member 1 
tilm, 
similar to LOC150383 protein 
pre-B-cell leukemia transcription factor 3 
nbonuclease H2, subumt Β 
Transcribed locus 
Transcribed locus 
similar to TTC30B protein 
similar to hypothetical protein MGC13204 




































































































In the present study we examined differential gene expression between Adox treated 
and control chick embryos in order to identify genes that are involved m neural tube 
closure and are sensitive for changes in methylation. Inhibition of methylation by 
Adox resulted in the up regulation of Λ5 probesets and the down regulation of 32 
probesets in our in vitro chick embryo model. Fifteen genes were selected for valida­
tion by QPCR analysis and the up regulation of the genes PSPH, ULK1 and CXCL12/ 
SDF-1 could be confirmed. 
Methylation is part of the epigenetic code, which is not determined by the DNA se­
quence itself, but by chemical modifications as DNA methylation, histone modifi­
cations and RNA associated silencing2 2 8 2 2 '. DNA methylation patterns are repro-
grammed during early embryogenes216, possibly making the embryo more vulnerable 
for an impaired methylation. Several studies have indirectly suggested DNA meth­
ylation to be one of the mechanisms underlying the complex etiology of these birth 
defects54 'i"™?*™. 
In a recent study from our group we demonstrated that global DNA methylation was 
decreased in spina bifida patients relative to pediatric controls (chapter 6). Global 
DNA methylation may however reflect the methylation of a variety of structures like 
transposable elements, regulatory sequences, repetitive elements or genes2 1'2 2 4. In 
the present study we therefore examined the effect of inhibition of methylation on 
gene expression in our in vitro chick embryo model in order to identify genes whose 
expression is regulated by changes in methylation and thus may be involved in neu-
rulation. 
We previously demonstrated that inhibition of methylation by Adox in our in vitro 
chick embryo model resulted m a decreased AdoMet/AdoHcy ratio as well as a dose-
dependent widening of the ANP38. In the present study we demonstrated that in­
hibition of methylation by Adox in our m vitro chick embryo model resulted m the 
up regulation of Λ5 probesets and the down regulation of 32 probesets, using the 
Affymetnx Genechip® Chicken Genome Array that contains 38,835 probesets cor­
responding to over 28,000 avian genes. The fifteen genes selected for validation by 
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QPCR analysis were all up regulated in the Adox treated chick embryos using micro-
array experiments, met the four criteria that were set and most of the genes are part 
of molecular pathways that are essential for proper neural tube closure. Since the up 
regulation of the genes PSPH, ULK1 and CXCL12/SDF-1 could be demonstrated by 
both microarray and QPCR analysis, these three genes are of particular interest. 
The enzyme phosphoserme phosphatase (PSPH) catalyzes the last step in the bio-
synthesis of the nonessential ammo acid L-senne. L-serine is a major source of 
one-carbon groups, providing formyl groups for purine synthesis and methyl groups 
for pynmidine synthesis and homocysteine remethylation231232. By transferring its 
one-carbon group to folates, serine is converted into glycine which plays important 
roles m the central nervous system232 L-senne can also be converted into D-serme, 
which has been suggested to be essential for brain development233. Une (uncoordi-
nated movement]-51 -like kinase 1 (ULK1 ) is part of a novel subfamily of evolutionary 
conserved serine/threonine kinases. Serine/threonine protein kinases phosphory-
late the hydroxyl group of serines and threonines using the phosphate group of ATP, 
which may results m functional changes of the target protein by affecting enzyme » 
Table 21 
Microarray and QPCR results for the 





















































































like nuclear factor n-pac) 2 231 0.086 1.11 0.39 
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activity. ULK1 has been demonstrated to play an important role in axon formation 
and elongation234·235 and endocytosis234·237. Alpha chemokines, also called CXC che-
mokines, are a family of small chemoattractant molecules important for the develop-
ment and organization of the hematopoietic/lymphopoietic system238-239. Chemokine 
(C-X-C motif) ligand 12/stromal cell-derived factor 1 (CXCL12/SDF-1) is a member 
of this family and is a potent chemoattractant for lymphocytes and monocytes240and 
mediates the migration of haematopoietic stem cells to the bone marrow241. Besides 
its role m inflammatory processes and the immune system, CXCL12/SDF-1 has also 
been suggested to play a role during morphogenesis and development of the central 
nervous system242. Together with its receptor CXCR4, CXCL12/SDF-1 may direct the 
migration of neural crest cells243244. 
Taking into account the functions of serine, the most likely explanation for the up 
regulation of PSPH in our in vitro chick embryo is to compensate for the inhibition of 
methylation by Adox. PSPH up regulation wil l likely result in increased serine syn-
thesis and subsequent increased donation of one-carbon groups to the folate cycle, 
hereby increasing one-carbon groups available for purine and pyrimidine synthesis 
and transmethylation reactions. Although ULK1 and CXCL12/SDF-1 cannot be di-
rectly linked to a pathway involved m NTD etiology, they are present in the brain dur-
ing embryonic development and were up regulated in our m vitro chick embryo and 
thus may be involved in proper neural tube closure. 
To establish whether the up regulation of PSPH, ULK1 and CXCL12/SDF-1 is indeed 
caused by changes in DNA methylation, the next step would be to look at the gene 
specific methylation patterns of the promoter and coding regions of these genes, 
using bisulfite sequencing245246 and compare the methylation patterns between Adox 
treated and control chick embryos. In addition, functional studies should be conduct-
ed to test whether chick embryos with up regulated PSPH, ULK1 or CXCL12/SDF-1 
gene expression present the same phenotype as the Adox treated chick embryos. In 
humans, the association between PSPH, ULK1 and CXCL12/SDF-1 and NTDs can be 
examined by screening these genes for functional SNPs and determining the effect 
of these SNPs on NTD risk using genetic association studies in large human NTD 
populations. 
In the present study we demonstrated that inhibition of methylation in our in vitro 
chick embryo model results in differential gene expression. Of all differentially ex-
pressed genes, 15 genes were selected for validation by QPCR analysis based on four 
criteria. The genes whose up regulation could not be confirmed by QPCR analysis, 
stil l require further investigation, since several of these genes are part of molecular 
pathways essential for neural tube closure. The three genes that were confirmed by 
QPCR analysis. PSPH, ULK1 and CXCL12/SDF-1, have never been described m rela-
tion to NTDs before. If the up regulation of these genes is indeed caused by changes 
in DNA methylation and is related to the NTD phenotype observed in our in vitro chick 
embryo model, we wil l not only have identified new genes implicated in neurulation, 
112 
but this wil l also strengthen the hypothesis that an impaired DNA methylation is one 
of the mechanisms underlying the complex etiology of NTDs 
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For more than 20 years now, it is known that women can reduce their risk of having 
a NTD affected child by taking vitamins containing folic acid penconceptionally"522''7 
Despite this major clinical success, the mechanisms underlying this beneficial effect 
of folic acid remain unclear This thesis aims to identify mechanisms underlying NTD 
etiology by identifying genetic risk factors for spina bifida (Part 1) and by examin-
ing the hypothesis that an impaired methylation lies at the basis of NTDs iPart 2), 
hereby exploring mechanisms that may be responsible for the beneficial effect of 
penconceptional folic acid supplementation in relation to these birth defects 
Part 1 Genetic variation 
Part 1 of this thesis describes the candidate gene approach that was conducted to 
identify genetic risk factors for spina bifida 
Folic acid m vitamin supplements and in fortified foods is unreduced and requires the 
action of DHFR before it can participate in cellular processes In addition, DHF that 
is formed in the folate cycle is converted into THF by the action of DHFR The DHFR 
gene is therefore a good candidate to examine m relation to NTDs A 19-bp deletion 
in mtron-l and a 9-bp repeat m the 5 UTR of the DHFR gene were not associated 
with DHFR gene expression or spina bifida risk in our population (Chapter 2) How-
ever, no firm conclusions can be drawn, since the 19-bp deletion has been associ-
ated with an increased risk of having spina bifida affected offspring"2 as well as an 
increased DHFR gene expression2'9 and the 9-bp repeat has not been examined in 
relation to spina bifida before Nevertheless, the observation that the coding region 
of the DHFR gene contained no variation m 20 individuals whose DHFR gene was 
sequenced177 suggests that genetic variants within the DHFR gene that affect DHFR 
gene expression or DHFR function are not tolerated and therefore are not likely to 
play a role m NTD etiology 
The THF that is formed out of DHF can be converted into 10-formyl, 5,10-methenyl 
and 5,10-methylene derivatives by the action of the tn-functional MTHFD1 enzyme 
that hereby plays a central role m the folate cycle Since the (intermediate) products 
of the reactions catalyzed by MTHFD1 are important substrates for methionine, pu-
rine and pyrimidme synthesis, genetic variants in the MTHFD1 gene could be risk 
factors for NTDs In our study population, the 1958G>A SNP in the MTHFD1 gene did 
not affect spina bifida risk m both mothers and children100 (Chapters) Since this is m 
116 
fi Discussion and future perspectives 
contrast with previously published studies that reported an association between the 
MTHFD1 1958G>A SNP and NTD risk101 103. it remains unclear whether the MTHFD1 
1958G>A SNP is associated with NTD risk and more studies in larger study popula-
tions should be conducted 
5-MethylTHF is the predominant form of folate m the plasma and m the cell 5-me-
thylTHF can donate its methyl group to homocysteine via the cofactor cob(l)alamin 
and the MTR enzyme CoblDalamm can be oxidized to cob(ll)alamin rendering an 
inactive MTR-cob(ll)alamin complex, which results in an impaired remethylation of 
homocysteine to methionine The MTR-cob(ll)alamin complex can be reactivated by 
the MTRR enzyme via reductive methylation The 66A>G SNP in the MTRR gene has 
been examined in relation to NTD risk in several studies Whether there is a possible 
association between this genetic variant and NTD risk remains unclear128"11 U3 even 
as which of the alleles is the high risk allele'697127 The presence of an association 
between the MTRR 66A>G SNP and spina bifida risk m the mother, child or both127128 
is also debated We identified the MTRR 66GG genotype as a risk factor for mothers 
to give birth to a child with a spina bifida and this risk became more pronounced m 
combination with the MTHFR 677TT genotype and elevated plasma MMA concentra-
tions (Chapter 4) In an attempt to disentangle the genetics of mother and child we 
performed a TDT to test whether the association between the MTRR 66A>G SNP and 
spina bifida risk was the result of a genotype effect in the child There was no prefe-
rential transmission of the G allele from parents to spina bifida affected child, indi-
cating that the G allele does not increase spina bifida risk via the child By conducting 
a meta-analysis we placed our research findings in the context of published data 
and at the same time objectively reviewed the literature present on the association 
between the MTRR 66A>G SNP and NTD risk m both mothers and children (Chapter 
6) The meta-analysis confirmed our previous findings that the MTRR 66GG genotype 
is a maternal NTD risk factor and does not affect NTD risk in the child 
From this study we can conclude that the MTRR 66GG genotype is a maternal spina 
bifida risk factor From the possible interaction that we observed between the MTRR 
66GG genotype and elevated plasma MMA concentrations, we can infer that mater-
nal intracellular vitamin B12 status might play an important role in NTD etiology, 
especially under specific conditions e g when having the MTRR 66GG genotype The 
importance of vitamin B12 m relation to NTDs has been examined m several studies 
by looking at plasma vitamin B^ 2 " 2 5 0 and amniotic fluid vitamin B12 concentra-
tions251252 Since total plasma vitamin B12 concentration is a poor indicator of the 
intracellular vitamin B12 status, because only 20% of the vitamin B12 present in 
plasma is bound to transcobalamm (TC) and transported into the cell, the relation 
between vitamin B12 and NTD risk has also been studied by looking at plasma holo-
transcobalamm150 and plasma MMA concentrations253 Seventeen relatively small 
case-control studies, conducted between 1980 and 2002 that investigated the as-
sociation between vitamin B12 and NTD risk have been systematically reviewed25' 
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Based on this review there seems to be a moderate association between maternal 
vitamin B12 status and the chance of giving birth to a NTD affected child25'. In order 
to draw firm conclusions on the relation between vitamin B12 and NTDs, a large 
double-blind randomized controlled trial should be conducted to study the effect of 
penconceptional vitamin B12 supplementation in relation to NTD risk. Since the risk 
reduction associated with vitamin B12 supplementation is expected to be much low-
er than that associated with folic acid and it is unethical and therefore not possible 
to withhold folic acid from women that want to get pregnant, trials on vitamin B12 
supplementation in relation to NTDs will have to be much larger, and are therefore 
less feasible, than the ones performed for periconceptional folic acid supplementa-
tion. 
Table 22 
Genetic variants in genes related to the 
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The study on the MTRR 66A>G SNP and spina bifida risk furthermore shows the 
value and importance of examining gene-gene and gene-environment interactions 
when studying a disease with a complex etiology. Since NTDs are multifactorial in 
origin, they are very likely to be caused by both genetic and environmental factors. 
In order to identify risk factors for NTDs and to make assumptions about possible 
mechanisms underlying these birth defects, it is of great importance to study both 
gene-gene and gene-environment interactions. 
Genetic variants in genes that encode enzymes that are not directly located or linked 
to the folate cycle but do affect or interact with this cycle could also be risk factors 
for NTDs. The 894G>T SNP in the endothelial derived nitric oxide synthase (N0S3] 
gene is such a genetic variant, being associated with elevated plasma homocyste­
ine concentrations in nonsmokers with low serum folate concentration204 as well as 
with embryonic spina bifida risk205. Conducting both a case-control study and a TDT, 
the N0S3 894G>T SNP could not be associated with spina bifida risk in mothers or 
children in our population (Chapter 5). In combination with the MTHFR 677TT geno­
type or elevated plasma homocysteine concentrations, the N0S3 894GT/TT genotype 
increased maternal spina bifida risk significantly, indicating a role for the homo­
cysteine metabolism in the detrimental effects asserted by the N0S3 894G>T SNP. 
Again, this study demonstrates the importance of examining gene-gene and gene-
environment interactions. The possible interactions found in our study enabled us to 
postulate mechanisms that might play a role in NTD etiology. 
One major drawback of the studies performed m Part 1 of this thesis is the lack of 
power to detect small associations between genetic variants and spina bifida risk, 
which is mainly caused by our relatively small study population. Since we used dif­
ferent study designs to examine possible associations between genetic variants and 
spina bifida risk and always worked from a mechanistically point of view, our stud­
ies can however sti l l contribute to the identification of mechanisms responsible for 
NTDs. Moreover, many relatively small studies on the association between a genetic 
variant and NTD risk that all point in the same direction, can be just as informative as 
one large genetic association study. In this light, meta-analyses are a valuable tool m 
objectively reviewing the data present in literature and can help determine the pre­
sence or absence of genetic associations. 
Of all the variants studied in Part 1 and reviewed in Chapter 1 of this thesis, the 
MTRR 66A>G SNP and the MTHFR 677C>T SNP seem to be the only genetic risk fac­
tors for NTDs (table 22). Considering the multifactorial etiology of NTDs, it is how­
ever very likely that there are more genetic risk factors for these birth defects. For 
several genetic variants in genes encoding enzymes in the folate cycle and homocys­
teine metabolism, their relation to NTDs stil l remains to be established and studies 
in large study populations, in which small association can be identified, are neces-
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sary. In addition, exploration of other genes than those encoding enzymes directly 
involved or related to the folate cycle in study populations that are large enough to 
identify small genetic associations is warranted. New strategies, like the SNP array, 
that enables the identification of thousands of polymorphisms at the same time, is a 
helpful tool that can be used in future research to identify new genetic risk factors of 
NTDs. In search for NTD risk factors it is furthermore essential to look at interplay 
of genetics and environmental factors because of the multifactorial etiology of these 
birth defects. 
Part 2 Methylation 
It is becoming more and more evident that besides genetic variation and environ-
mental factors, epigenetic mechanisms also play an important role in the etiology of 
complex diseases. Since NTDs are multifactorial in origin, epigenetic mechanisms 
are likely to be involved m their complex etiology. DNA methylation, which is repro-
grammed during early embryogenesis216, is part of the epigenetic code and is the 
chief regulator of gene expression213, has been hypothesized to be associated with 
NTDs54. In Part 2 of this thesis the hypothesis that an impaired methylation is one of 
the mechanisms underlying NTDs is examined. 
Many studies have suggested a link between an impaired DNA methylation and NTD 
risk. The 6 7 7 0 T SNP in the MTHFR gene has been associated with reduced global 
DNA methylation as well as NTD risk7173. Inactivation of the DNA methyltransferase 
DNMT3B disrupts de novo DNA methylation m mice and results in multiple deve-
lopmental defects including NTDs74. Inhibition of methylation in both mice and chick 
embryos results in a reduced AdoMet/AdoHcy ratio and affects cranial neurula-
tion3876. And the AdoMet/AdoHcy ratio in mothers of a NTD affected child has been 
demonstrated to be decreased220. Only one study however, has actually examined 
DNA methylation status in relation to NTDs230. In that study the AdoMet/AdoHcy ratio 
and DNA methylation were both decreased in a single case with trisomy 21 and spina 
bifida230. 
In Chapter 6 of this thesis we have measured global DNA methylation in spina bifida 
patients and pediatric controls, using a new highly sensitive and specific LC-ESI-MS/ 
MS method262 and demonstrated global DNA methylation to be decreased in spina bi-
fida patients relative to pediatric controls. The results of our study are in line with the 
data of previous studies that all indirectly pointed towards an association between 
an impaired DNA methylation and NTD risk38·71727476220. However, to our knowledge 
our study was the first to directly measure and link a reduced methylation of DNA to 
spina bifida. 
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The major question that follows from the observations in Chapter 6 is what this de-
crease in global DNA methylation in spina bifida patients means. It may be sugges-
ted that the decrease in global DNA methylation observed in spina bifida patients is 
likely to be restricted to areas of the genome formerly described as "junk" DNA that 
have no function and that therefore the decrease in global DNA methylation is un-
likely to be involved m spina bifida etiology. However, it is becoming more and more 
clear that there is no such thing as "junk" DNA, which is nicely illustrated by the 
abundance of transposable elements (TEs) present in the genomes of many orga-
nisms22'. TEs were long dismissed as useless "junk" DNA but have recently emerged 
as major contributors in the translation of genotype to phenotype and appear to be 
under epigenetic control224. The observed decrease in global DNA methylation in 
spina bifida patients (Chapter 6) may therefore just as well be functional in that it (il 
may reflect changes in DNA methylation of TEs or other regulatory sequences that 
have an effect on gene expression of genes involved in neural tube closure or (lij may 
directly affect the methylation, and subsequently the expression, of genes that play 
a role m proper neural tube closure. 
To further investigate the association between DNA methylation and NTDs, it would 
be of great interest to look at gene specific methylation. To conduct such an ap-
proach, genes that are associated with neural tube closure and are also sensitive for 
changes m methylation wil l have to be identified. By examining differences in gene 
expression between chick embryos treated with the methylation inhibitor Adox that 
have a decreased Ad o Met/Ad o Hey ratio and exhibit a NTD phenotype38 and control 
chick embryos, we identified genes that might play a role in neural tube closure 
and whose expression may be regulated by changes in methylation. In the study de-
scribed in Chapter 7 of this thesis, we identified 45 probesets that were up regulated 
(fold change ï 2.0, ρ < 0.05] and 32 probesets that were down regulated (fold change 
ί 0.5, ρ < 0.05) in Adox treated chick embryos, using the Affymetrix Genechip® 
Chicken Genome Array. Of all the genes that were differentially expressed, 15 genes 
were selected for validation by QPCR analysis and the differential gene expression 
of phosphosenne phosphatase (PSPH), unc-51-like kinase 1 (ULK1) and chemokme 
[C-X-C motif) ligand 12/stromal cell-derived factor 1 (CXCL12/5DF-1) could be con­
firmed by QPCR analysis (Chapter 7). 
Since the 12 genes that could not be confirmed by QPCR analysis were up regulated 
using microarray analysis and several of these genes are part of molecular pathways 
essential for neural tube closure, these genes are stil l of interest in relation to NTDs 
and require further investigation in future research. The up regulation of the genes 
PSPH, ULK1 and CXCL12/SDF-1 was observed using two different techniques and is 
therefore of particular interest. 
The next step would be to determine whether the up regulation of PSPH, ULK1 and 
CXCL12/SDF-1 is indeed caused by DNA hypomethylation by looking at the gene spe-
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cific methylation patterns of these genes using bisulfite DNA sequencing2"-2" and 
comparing these patterns between Adox treated and control chick embryos. Promo-
ters are key targets for epigenetic control and thus key targets to look for differences 
in gene specific methylation255. Since it has been demonstrated that promoters that 
contain CpG islands are usually unmethylated255 the methylation of the promoters of 
PSPH, ULK1 andCXCL12/SDF-1 should especially be examined if they do not contain 
CpG islands. In addition the methylation of CpG dinucleotides present in the coding 
regions of PSPH, ULK1 and CXCL12/SDF-1 can be examined. It has been demon-
strated that CXCL12/SDF-1 expression in humans is regulated by methylation of its 
promoter256-257, making this an excellent candidate to start with. The up regulation of 
PSPH, ULK1 and CXCL12/SDF-1 could also be a reaction to compensate changes in 
gene expression of other genes that are sensitive for changes in methylation. 
To test if PSPH, ULK1 and CXCL12/SDF-1 play a role in proper neural tube closure, 
functional studies wil l have to be conducted in our in vitro chick embryo model to 
see whether an up regulation of these genes results m the same phenotype as that 
observed after administration of Adox. Since RNA interference inhibits gene expres-
sion258 and PSPH, ULK1 and CXCL12/SDF-1 are up regulated (Chapter?), RNA inter-
ference can only be used to silence possible repressors of these genes. Chemicals 
that stimulate PSPH, ULK1 and CXCL12/SDF-1 gene expression could also be used 
to up regulate these genes. If the products of the up regulated genes are also more 
abundant in Adox treated chick embryos, which can be tested by performing a west-
ern blot, administration of high amounts of these proteins to our in vitro chick em-
bryo model would be another possibility to perform functional tests. 
Since the up regulation of PSPH, ULK1 and CXCL12/SDF-1 was observed in chick 
embryos, the obtained results are difficult to extrapolate to the human situation. 
To get more insight into the possible role of PSPH. ULK1 and CXCL12/SDF-1 in the 
etiology of human NTDs, the relation of functional SNPs in these genes and NTD risk 
could be examined by performing genetic association studies in NTD study popula-
tions. Screening of the NCBI SNP database revealed 4 functional SNPS m the ULK1 
gene and 1 functional SNP in the CXCL12/SDF-1 gene that could be screened for. 
Sequencing the genes PSPH, ULK1 and CXCL12/SDF-1 may reveal other functional 
SNPs that can be screened for as well. 
In the future large scale studies m which DNA methylation patterns of healthy new-
borns and those with a NTD wil l be characterized and compared using array based 
approaches259261 wi l l shed more light on the association between an impaired DNA 
methylation and NTD etiology in humans and wil l probably identify new genes essen-
tial for neural tube closure. If an impaired DNA methylation is indeed associated with 
NTD etiology, the next step wil l than be to examine whether folic acid supplemen-
tation of the mother can affect DNA methylation patterns m her child as has been 
demonstrated already for Agouti mice218. 
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Schematic representation of the risk fac-
tors for NTDs that have been identif ied/ 
discussed in this thesis. 
The ultimate goal of identifying genes that are under epigenetic control and in-
volved in NTD etiology is the identification of molecular pathways that are essential 
for proper neural tube closure and can be manipulated by altering diet or lifestyle, 
hereby preventing NTDs. 
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2 Summary and Samenvatting 
Summary 
With a frequency of one m every thousand life born, neural tube defects (NTDs) are 
among the most common congenital malformations NTDs occur during the third 
and fourth week of gestation, at a time when women are just aware of the fact that 
they are pregnant The two most common forms of neural tube defects are spina 
bifida and anencephaly, severe malformations that often result m lifelong handicaps 
and sometimes even death Penconceptional folic acid supplementation reduces the 
risk of having a NTD affected pregnancy by 50-70% The mechanisms underlying this 
preventive effect of folic acid supplementation remain to be elucidated 
This thesis aims to identify mechanisms underlying the complex etiology of NTDs by 
examining associations between SNPs m candidate genes and spina bifida risk (Part 
1) and by examining the hypothesis that an impaired methylation lies at the basis of 
these birth defects (Part 2) 
Chapter 1 of this thesis is a general introduction on the process of neurulation, 
NTDs, the folate cycle and closely related homocysteine metabolism and possible 
mechanisms underlying NTD etiology It furthermore gives an overview of genetic 
variants in genes encoding enzymes involved in the folate cycle and homocysteine 
metabolism and their relation to NTD risk 
Part 1 Genetic variation 
In Chapter 2 possible associations between two genetic variants m the DHFR gene 
and spina bifida risk and DHFR gene expression are examined The 19-bp deletion m 
mtron-l and the 9-bp repeat in the 5 UTR of the DHFR gene were not associated with 
spina bifida risk m both mothers and children The DHFR 9-bp repeat 6/6 genotype 
possibly increases DHFR gene expression 
The 1958G>A SNP in the MTHFD1 gene is discussed in Chapter 3 of this thesis In 
our study population, the MTHFD1 1958AA genotype was not associated with an in-
creased risk of spina bifida In mothers, the MTHFD1 1958GA genotype might even 
be associated with a decreased spina bifida risk and also resulted m elevated RBC 
folate concentrations 
The next candidate gene investigated in relation to spina bifida risk is the MTRR 
gene In Chapter t* we demonstrate that the MTRR 66GG genotype increases the risk 
of having a spina bifida affected child twofold and that this risk increases to 5 5 fold 
when mothers also have a low intracellular vitamin B12 status Our observation that 
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the MTRR 66GG genotype is a maternal spina bifida risk factor was confirmed by the 
meta-analyses that we conducted in Chapter A. 
The N0S3 gene does not encode an enzyme involved in the folate cycle or homocys­
teine metabolism, but the 894G>T SNP in this gene has been associated with homo­
cysteine and NTD risk. In Chapter 5 we do not find an association between the N0S3 
894G>T SNP and spina bifida risk. In combination with the MTHFR 677TT genotype 
or elevated plasma homocysteine concentrations, the N0S3 894GT/TT genotype in­
creased maternal spina bifida risk 4.5 and 3.k fold respectively. 
Part 2 Methylation 
In Chapter 6 global DNA methylation in spina bifida patients and pediatric controls 
was measured using a new highly sensitive and specific LC-ESI-MS/MS technique. 
Global DNA methylation ratio was significantly reduced in spina bifida patients rela­
tive to the pediatric controls and a global DNA methylation ratio m the lowest quartile 
of the control distribution was associated with a 3.9 fold increased spina bifida risk. 
To identify genes that may be sensitive for changes in methylation and are involved m 
neural tube closure, differences m gene expression between chick embryos treated 
with the methylation inhibitor Adox and control chick embryos were examined in 
Chapter 7. Using the Affymetnx Genechip® Chicken Genome Array, we identified 
Λ5 probesets that were up regulated (fold Ï 2.0, ρ < 0.05) and 32 probesets that were 
down regulated m Adox treated chick embryos [fold ί 0.5, ρ < 0.05). Of the 15 genes 
selected for validation by QPCR analysis, the differential gene expression of phos-
phoserme phosphatase (PSPH), unc-51-like kinase 1 (ULK1) and chemokme (C-X-C 
motif) ligand 12/stromal cell-derived factor 1 (CXCL12/SDF-1) could be confirmed. 
The results of all the studies described in this thesis are discussed m Chapter 8 as 
well as possible directions for future research. 
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Samenvatting 
Met een frequentie van 1 op de 1000 levend geborenen, zijn neurale buis defecten 
(NBD) een van de meest voorkomende aangeboren afwijkingen NBD ontstaan ge-
durende de derde en vierde week van de zwangerschap, wanneer de meeste vrou-
wen nog met weten dat ze zwanger zijn Onvolledige sluiting van de neurale buis 
resulteert m spina bifida (een open ruggetje] of anencefalie (kattenkopje), ernstige 
aandoeningen die vaak leiden tot levenslange handicaps of zelfs de dood Inname 
van foliumzuur vóór en gedurende de eerste weken van de zwangerschap, reduceert 
de kans op het krijgen van een kind met NBD met 50-70% De mechanismen die aan 
dit preventieve effect van foliumzuur ten grondslag ligen, zijn echter met bekend 
Dit proefschrift beoogt de mechanismen die ten grondslag liggen aan NBD te onder-
zoeken door middelvan genetische associatie studies (Deel 1) en de bestudering van 
een verminderde methylermg als mogelijk mechanisme betrokken bij het ontstaan 
van NBD (Deel 2) 
Hoofdstuk 1 van dit proefschrift omvat een algemene inleiding betreffende het pro-
ces van neurale buis sluiting, NBD, de folaatcyclus en het gerelateerde homocys-
teine metabolisme en mechanismen die mogelijk een rol spelen bij het ontstaan 
van NBD Tevens wordt er een overzicht gegeven van genetische varianten m genen 
coderend voor enzymen die betrokken zijn in de folaatcyclus en het homocysteine 
metabolisme en hun relatie tot NBD 
Deel 1 Genetische variatie 
In Hoofdstuk 2 worden mogelijke associaties tussen twee genetische varianten m 
het DHFR gen en spina bifida risico en DHFR gen expressie bestudeerd De 19-bp 
deletie m intron 1 en de 9-bp repeat m het 5 DTR van het DHFR gen zijn beiden met 
geassocieerd met spina bifida in moeders en kinderen Het DHFR 9-bp repeat 6/6 
genotype verhoogt mogelijk de DHFR gen expressie 
De 1958G>A 5NP m het MTHFD1 gen wordt besproken m Hoofdstuk 3 van dit proef-
schrift In onze studie populatie is het MTHFD1 1958AA genotype geen risico factor 
voor spina bifida Het MTHFD1 1958GA genotype heeft mogelijk een beschermend 
effect op het krijgen van een kind met een spina bifida en is geassocieerd met een 
verhoogde folaat concentratie in rode bloedcellen m controle vrouwen 
Het volgende kandidaatgen dat onderzocht is m relatie tot spina bifida is MTRR In 
Hoofdstuk A laten we zien dat het MTRR 66GG genotype geassocieerd is met een 
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twee keer hoger risico op het krijgen van een kind met spina bifida en dat dit risico 
5,5 keer hoger is als de moeder naast het MTRR 66GG genotype ook een lage intra­
cellulaire vitamine B12 status heeft In hetzelfde hoofdstuk is ook een meta-analyse 
uitgevoerd die bevestigt dat het MTRR 66GG genotype een spina bifida risicofactor in 
de moeder is 
Het N0S3 gen codeert een enzym dat met betrokken is m de folaatcyclus of het ho­
mocysteine metabolisme, maar de 894G>T 5NP m dit gen is wel m relatie gebracht 
met homocysteine en NBD In Hoofdstuk 5 van dit proefschrift kunnen we geen as­
sociatie vinden tussen de N0S3 89^G>T SNP en spina bifida risico m onze studie po­
pulatie Echter, m combinatie met het MTHFR 67711 genotype of verhoogde plasma 
homocysteine concentraties, verhoogt het N0S3 89Λ6Τ/ΤΤ genotype de kans op het 
krijgen van een kind met spina bifida Λ,5 en 3,Λ keer respectievelijk 
Deel 2 Methylering 
In Hoofdstuk 6 is de globale DNA methylering m spina bifida patiënten en controle 
kinderen gemeten met behulp van een nieuwe, sensitieve en specifieke LC-ESI-MS/ 
MS techniek De globale DNA methylering was significant verlaagd m spina bifida 
patiënten ten opzichte van de controle kinderen en een globale DNA methylering m 
het laagste kwartiel van de controle distributie verhoogde de kans op het krijgen van 
spina bifida 3,9 keer 
Om genen te identificeren die te beïnvloeden zijn door methylering en mogelijk 
betrokken zijn bij de sluiting van de neurale buis, hebben we m Hoofdstuk 7 de 
verschillen m gen expressie tussen kippenembryo s behandeld met de methyler-
mgsremmer Adox en controle kippenembryo s bestudeerd Met behulp van de Af-
fymetnx Genechip® Chicken Genome Array zijn 45 opgereguleerde probesets [fold ï 
2 0, ρ < 0 05] en 32 downgereguleerde probesets (fold « 0 5, ρ < 0 05) geïdentificeerd 
m kippenembryo s behandeld met Adox Voor de genen phosphosenne phosphatase 
(PSPH), unc-51-like kinase 1 (ULKI) en chemokine [C-X-C motief) ligand 12/stromal 
cell-derived factor (CXCL12/SDF-1) kon het verschil m genexpressie dat was aan-
getoond met behulp van microarray worden bevestigd met behulp van QPCR analyse 
De resultaten van alle studies die m dit proefschrift zijn beschreven evenals mogelijk 
vervolgonderzoek worden m Hoofdstuk 8 bediscussieerd 
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"Last but not least." Zo ook in dit boekje waarin ik m dit laatste hoofdstuk graag 
alle mensen wil bedanken die op welke manier dan ook betrokken zijn geweest bij 
mijn promotie en het tot stand komen van dit boekje. Daarbij wi l ik graag een aantal 
mensen m het bijzonder noemen. 
Allereerst mijn co-promotor Henk Blom. Beste Henk. ik wil je bedanken voor je ad-
viezen, begeleiding en onuitputtelijke bron aan opbeurende woorden als ik het weer 
eens met zag zitten. Je deur stond altijd voor me open en hoe druk je het ook had, er 
was altijd tijd voor een overleg of goed gesprek. Bedankt dat je me de vrijheid hebt 
gegeven om mijn eigen keuzes te maken binnen mijn promotieonderzoek. Ik heb 
ontzettend veel van je geleerd! 
Mijn andere co-promotor is Martin den Heijer. Beste Martin, je was mijn vraagbaak 
voor alle statistische en epidemiologische problematiek betreffende mijn onderzoek 
en daar ben ik je ontzettend dankbaar voor1 Je kundige en altijd heldere uitleg over 
statistische toetsen en testen reduceerde de, in mijn ogen, "abracadabra" wereld 
van de statistiek m korte tijd tot een te bevatten en te begrijpen kost. Ik wil je hier 
graag voor bedanken. 
Vervolgens mijn promotor Ron Wevers. Beste Ron, als hoofd van het Laboratorium 
Kindergeneeskunde en Neurologie ben je wat minder nauw betrokken geweest bij 
mijn promotieonderzoek. Ik waardeer het daarom enorm dat je mijn promotor wilt 
zijn! 
Mijn paranimfen Sandra Heil en Henkjan Gellekmk. Sandra, je hebt me gedurende 
mijn hele promotietraject enorm geholpen met mijn onderzoek, m het bijzonder 
met de microarray experimenten. Daarnaast hebben we samen heel veel lol gehad, 
vooral als we weer eens een geintje met Henkjan uithaalden... Heel erg bedankt voor 
alles1 Henkjan, ook jij stond altijd voor me klaar en toen ik in april 2003 aan mijn pro-
motie begon, heb jij me ingewerkt op het lab. Je relativerende vermogen en nuchtere 
Twentse kijk op zaken, heeft me door menig promotiedipje heen geholpen. Bedankt 
voor je engelen geduld1 Ik ben ontzettend blij dat jullie vandaag naast me staan! 
Suzanne Vloet wil ik bedanken voor haar inzet en hulp gedurende de laatste twee 
jaar van mijn promotieonderzoek. Beste Suus, je hebt heel wat DNA'tjes geïsoleerd 
en QPCR experimenten gerund. En ook al zat het onderzoek soms tegen, je eeuwige 
lach en positieve instelling ben je gelukkig nooit verloren1 Ik wens je heel veel succes 
bij antropogenetica. 
Uyen Nguyen, José Mulder en Janneke van der Loop hebben me tijdens hun stages 
bijgestaan. Beste Uyen, ik wil je bedanken voor je inzet en de gezelligheid die je met 
je meebracht. Jou werk heeft uiteindelijk geresulteerd m een mooi artikel en daar 
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mag je trots op zijn1 Succes m je verdere carrière 
José en Janneke, ik wil jullie bedanken voor alle genotypenngen die jullie voor mijn 
onderzoek hebben verricht José, heel veel succes met je opleiding geneeskunde en 
Janneke, ik ben benieuwd wat de volgende stap m je carrière zal zijn, HLO of toch 
een andere richting 
Voor het kweken en verzamelen van kippenembryo's ben ik een halfjaar naar Maas-
tricht gegaan Ik wil graag iedereen bedanken voor de gastvrijheid en de gezellige 
pauzes, waarbij een groot stuk echte Limburgse vlaai natuurlijk met kon ontbreken1 
In het bijzonder wil ik graag Henny van Straaten, Johan Hekkmg en Els Terwmdt 
bedanken Beste Henny, je hebt me altijd m alle activiteiten van het lab en je groep 
betrokken en dankzij je heldere uitleg over embryologie en het kippenembryo heb ik 
veel van je geleerd, dankjewel1 Johan, bedankt voor alle uitleg en hulp zowel bij de 
kweek, het inleggen van de eieren en het vertalen van het voor mij vaak onverstaan-
bare "Maastnechs" m gewoon ABN Els, ook jou wil ik bedanken voor alle keren dat 
je m het weekend eieren voor me hebt ingelegd 
Tijdens mijn promotieonderzoek heb ik acht maanden op het laboratorium van Rich-
ard Fmnell m Houston mogen werken Dear Rick and Susanna, thank you so much 
for the warm welcome when I came to Houston You made me feel at home m Hous-
ton and I wi l l never forget the wonderful home-cooked Thanksgiving diner, the Ro-
deo and the Carparade I'm very happy that you can be here today1 
Robert, thanks to you my laboratory skills improved and expanded exponentially 
during my stay in Houston I really enjoyed working with you on the lab and our (al-
most) daily beers 
Analee and Denise, I wi l l never forget the wonderful Dutch corner you made for me 
in the graduate student office when I felt home sick Analee and Jason, thanks for 
all the times you picked me up from Favrot Towers to take me out for diner, a drink 
or a (3D) movie 
Dear Michelle and Melissa, you're the funniest and craziest technicians that I've ever 
met1 You were always there for me and I had lots of fun during our weekly salsa 
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The observation that a simple intervention 
as maternal, folic acid intake before and 
during early pregnancy reduces the risk of 
having a child with a neural tube defect is 
a major clinical success. The mechanisms 
underlying this beneficial effect of folic acid 
however, remain to be elucidated. 
Our human studies demonstrate that a ge-
netic variant in the methionine synthase re-
ductase gene is a risk factor for having a 
spina bifida affected child, especially when 
the mother has a low vitamin B12 status. 
The studies conducted in our chick embryo 
model demonstrate that inhibition of methy-
lation results in an impaired closure of the 
neural tube and changes in the expression 
of specific genes. These genes may be re-
gulated by changes in DNA methylation and 
possibly play a role in the complex etiology 
of neural tube defects. 
One Carbon Metabolism and Neural Tube Defects -> Case open or closed? 
-> Ivon van der Linden 
